<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐cytokine targeted therapies for ANCA‐associated vasculitis - Bala, MM - 2020 | Cochrane Library</title> <meta content="Anti‐cytokine targeted therapies for ANCA‐associated vasculitis - Bala, MM - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008333.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐cytokine targeted therapies for ANCA‐associated vasculitis - Bala, MM - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008333.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008333.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐cytokine targeted therapies for ANCA‐associated vasculitis" name="citation_title"/> <meta content="Malgorzata M Bala" name="citation_author"/> <meta content="Jagiellonian University Medical College" name="citation_author_institution"/> <meta content="gosiabala@mp.pl" name="citation_author_email"/> <meta content="Teresa J Malecka-Massalska" name="citation_author"/> <meta content="Magdalena Koperny" name="citation_author"/> <meta content="Jagiellonian University Medical College" name="citation_author_institution"/> <meta content="Joanna F Zajac" name="citation_author"/> <meta content="Jarosław D Jarczewski" name="citation_author"/> <meta content="Jagiellonian University Medical College" name="citation_author_institution"/> <meta content="Wojciech Szczeklik" name="citation_author"/> <meta content="Jagiellonian University Medical College" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD008333.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/09/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008333.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008333.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008333.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis [*drug therapy, mortality]; Antibodies, Monoclonal, Humanized [administration &amp; dosage, adverse effects]; Churg-Strauss Syndrome [drug therapy]; Etanercept [administration &amp; dosage, adverse effects]; Granulomatosis with Polyangiitis [drug therapy]; Immunosuppressive Agents [*administration &amp; dosage, adverse effects]; Infliximab [administration &amp; dosage, adverse effects]; Microscopic Polyangiitis [drug therapy]; Numbers Needed To Treat; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Rituximab [administration &amp; dosage, adverse effects]; Secondary Prevention; Steroids [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008333.pub2&amp;doi=10.1002/14651858.CD008333.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xsb6SJyC";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008333\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008333\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ko","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008333.pub2",title:"Anti\\u2010cytokine targeted therapies for ANCA\\u2010associated vasculitis",firstPublishedDate:"Sep 29, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008333.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008333.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008333.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008333.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008333.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008333.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008333.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008333.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008333.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008333.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3378 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008333.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/appendices#CD008333-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/table_n/CD008333StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/table_n/CD008333StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐cytokine targeted therapies for ANCA‐associated vasculitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information#CD008333-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Malgorzata M Bala</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information#CD008333-cr-0005">Teresa J Malecka-Massalska</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information#CD008333-cr-0006">Magdalena Koperny</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information#CD008333-cr-0007">Joanna F Zajac</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information#CD008333-cr-0008">Jarosław D Jarczewski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information#CD008333-cr-0009">Wojciech Szczeklik</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information/en#CD008333-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 September 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008333.pub2">https://doi.org/10.1002/14651858.CD008333.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008333-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008333-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008333-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008333-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008333-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008333-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008333-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008333-abs-0001" lang="en"> <section id="CD008333-sec-0001"> <h3 class="title" id="CD008333-sec-0001">Background</h3> <p>Anti‐neutrophilic cytoplasmic antibodies (ANCA)‐associated vasculitis (AAV) are a group of rare auto‐inflammatory diseases that affects mainly small vessels. AAV includes: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Anti‐cytokine targeted therapy uses biological agents capable of specifically targeting and neutralising cytokine mediators of the inflammatory response. </p> </section> <section id="CD008333-sec-0002"> <h3 class="title" id="CD008333-sec-0002">Objectives</h3> <p>To assess the benefits and harms of anti‐cytokine targeted therapy for adults with AAV. </p> </section> <section id="CD008333-sec-0003"> <h3 class="title" id="CD008333-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (2019, Issue 7), MEDLINE and Embase up to 16 August 2019. We also examined reference lists of articles, clinical trial registries, websites of regulatory agencies and contacted manufacturers. </p> </section> <section id="CD008333-sec-0004"> <h3 class="title" id="CD008333-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) or controlled clinical trials of targeted anti‐cytokine therapy in adults (18 years or older) with AAV compared with placebo, standard therapy or another modality and anti‐cytokine therapy of different type or dose. </p> </section> <section id="CD008333-sec-0005"> <h3 class="title" id="CD008333-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD008333-sec-0006"> <h3 class="title" id="CD008333-sec-0006">Main results</h3> <p>We included four RCTs with a total of 440 participants (mean age 48 to 56 years). We analysed the studies in three groups: 1) mepolizumab (300 mg; three separate injections every four weeks for 52 weeks) versus placebo in participants with relapsing or refractory EGPA; 2) belimumab (10 mg/kg on days 0, 14, 28 and every 28 days thereafter until 12 months after the last participant was randomised) or etanercept (25 mg twice a week) with standard therapy (median 25 months) versus placebo with standard therapy (median 19 months) in participants with GPA/MPA; and 3) infliximab (3 mg/kg on days 1 and 14, before the response assessment on day 42) versus rituximab (0.375g/m<sup>2</sup> on days 1, 8, 15 and 22) in participants with refractory GPA for up to 12 months. None of the studies were assessed as low risk of bias in all domains: one study did not report randomisation or blinding methods clearly. Three studies were at high risk and one study was at unclear risk of bias for selective outcome reporting. </p> <p>One trial with 136 participants with relapsing or refractory EGPA compared mepolizumab with placebo during 52 weeks of follow‐up and observed one death in the mepolizumab group (1/68, 1.5%) and none in the placebo group (0/68, 0%) (Peto odds ratio (OR) 7.39, 95% confidence interval (CI) 0.15 to 372.38; low‐certainty evidence). Low‐certainty evidence suggests that more participants in the mepolizumab group had ≥ 24 weeks of accrued remission over 52 weeks compared to placebo (27.9% versus 2.9%; risk ratio (RR) 9.5, 95% CI 2.30 to 39.21), and durable remission within the first 24 weeks sustained until week 52 (19.1% mepolizumab versus 1.5% placebo; RR 13.0, 95% CI 1.75 to 96.63; number needed to treat for an additional beneficial outcome (NNTB) 6, 95% Cl 4 to 13). Mepolizumab probably decreases risk of relapse (55.8% versus 82.4%; RR 0.68, 95% CI 0.53 to 0.86; NNTB 4, 95% CI 3 to 9; moderate‐certainty evidence). There was low‐certainty evidence regarding similar frequency of adverse events (AEs): total AEs (96.9% versus 94.1%; RR 1.03, 95% CI 0.96 to 1.11), serious AEs (17.7% versus 26.5%; RR 0.67, 95% CI 0.35 to 1.28) and withdrawals due to AEs (2.9% versus 1.5%; RR 2.00, 95% CI 0.19 to 21.54). Disease flares were not measured. </p> <p>Based on two trials with different follow‐up periods (mean of 27 months for etanercept study; up to four years for belimumab study) including people with GPA (n = 263) and a small group of participants with MPA (n = 22) analysed together, we found low‐certainty evidence suggesting that adding an active drug (etanercept or belimumab) to standard therapy does not increase or reduce mortality (3.4% versus 1.4%; Peto OR 2.45, 95% CI 0.55 to 10.97). Etanercept may have little or no effect on remission (92.3% versus 89.5%; RR 0.97, 95% CI 0.89 to 1.07), durable remission (70% versus 75.3%; RR 0.93, 95% CI 0.77 to 1.11; low‐certainty evidence) and disease flares (56% versus 57.1%; RR 0.98, 95% CI 0.76 to 1.27; moderate‐certainty evidence). Low‐certainty evidence suggests that belimumab does not increase or reduce major relapse (1.9% versus 0%; RR 2.94, 95% CI 0.12 to 70.67) or any AE (92.5% versus 82.7%; RR 1.12, 95% CI 0.97 to 1.29). Low‐certainty evidence suggests a similar frequency of serious or severe AEs (47.6% versus 47.6%; RR 1.00, 95% CI 0.80 to 1.27), but more frequent withdrawals due to AEs in the active drug group (11.2%) compared to the placebo group (4.2%), RR 2.66, 95% CI 1.07 to 6.59). </p> <p>One trial involving 17 participants with refractory GPA compared infliximab versus rituximab added to steroids and cytotoxic agents for 12 months. One participant died in each group (Peto OR 0.88, 95% CI, 0.05 to 15.51; 11% versus 12.5%). We have very low‐certainty evidence for remission (22% versus 50%, RR 0.44, 95% Cl 0.11 to 1.81) and durable remission (11% versus 50%, RR 0.22, 95% CI 0.03 to 1.60), any severe AE (22.3% versus 12.5%; RR 1.78, 95% CI 0.2 to 16.1) and withdrawals due to AEs (0% versus 0%; RR 2.70, 95% CI 0.13 to 58.24). Disease flare/relapse and the frequency of any AE were not reported. </p> </section> <section id="CD008333-sec-0007"> <h3 class="title" id="CD008333-sec-0007">Authors' conclusions</h3> <p>We found four studies but concerns about risk of bias and small sample sizes preclude firm conclusions. </p> <p>We found moderate‐certainty evidence that in patients with relapsing or refractory EGPA, mepolizumab compared to placebo probably decreases disease relapse and low‐certainty evidence that mepolizumab may increase the probability of accruing at least 24 weeks of disease remission. There were similar frequencies of total and serious AEs in both groups, but the study was too small to reliably assess these outcomes. Mepolizumab may result in little to no difference in mortality. However, there were very few events. </p> <p>In participants with GPA (and a small subgroup of participants with MPA), etanercept or belimumab may increase the probability of withdrawal due to AEs and may have little to no impact on serious AEs. Etanercept may have little or no impact on durable remission and probably does not reduce disease flare. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008333-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008333-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008333-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008333-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008333-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008333-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008333-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008333-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008333-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008333-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008333-abs-0002" lang="en"> <h3>What are the benefits and risks of anti‐cytokine medicines for ANCA‐associated vasculitis?</h3> <p><b>Why this question is important</b> </p> <p>The body’s defence (immune) system fights injury or infection by sending white blood cells to surround and protect the affected area. This causes redness and swelling, called inflammation. </p> <p>Vasculitis is an inflammation of the blood vessels. In vasculitis, instead of reacting to harm, the immune system attacks healthy blood vessels. The reason for this reaction is often unknown. </p> <p>One rare type of vasculitis is antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV). AAV covers three different conditions that are grouped together because they all affect small blood vessels: </p> <p>‐ MPA: microscopic polyangiitis;</p> <p>‐ GPA: granulomatosis with polyangiitis; and</p> <p>‐ EPGA: eosinophilic granulomatosis with polyangiitis.</p> <p>The areas of the body most commonly affected are kidneys, lungs, joints, ears, nose and nerves. It is important to treat AAV early, to prevent serious damage to these organs. </p> <p>Currently, the recommended treatment for AAV is to use medicines that control the immune system and medicines against inflammation (steroids). However, this treatment causes serious unwanted effects. Medicines that target cytokines (small molecules that influence the immune system’s reactions) are an alternative option. To evaluate the benefits and risks of anti‐cytokine medicines, we reviewed the evidence from research studies. </p> <p><b>How we identified and assessed the evidence</b> </p> <p>First, we searched for all relevant studies in the medical literature. We then compared the results, and summarised the evidence from all the studies. Finally, we assessed how certain the evidence was. We considered factors such as the way studies were conducted, study sizes, and consistency of findings across studies. Based on our assessments, we categorized the evidence as being of very low, low, moderate or high certainty. </p> <p><b>What we found</b> </p> <p>We found four studies on a total of 440 adults from the USA and Europe. The average age of people ranged between 48 and 56 years. They received treatment for between 2 and 25 months, and were then followed for between 8 weeks and four years. Three studies compared anti‐cytokine medicines (mepolizumab, belimumab and etanercept) to a placebo (fake medicine) and one study compared two different anti‐cytokine medicines (rituximab versus infliximab). Three studies received at least partial funding from pharmaceutical companies. </p> <p><i>Mepolizumab versus placebo in people with EGPA that returned after, or did not respond to, initial treatment</i> </p> <p>Moderate‐certainty evidence indicates that mepolizumab probably reduces the likelihood of the disease returning within a year of treatment. </p> <p>Low‐certainty evidence suggests that mepolizumab:</p> <p>‐ may make little or no difference to mortality;</p> <p>‐ may increase the likelihood of the disease partially or fully disappearing for at least 24 weeks, and may increase the chances of this disappearance lasting for another six months at least; </p> <p>‐ may make little or no difference to unwanted events, serious unwanted events or withdrawal from studies due to unwanted events. </p> <p>The impact of mepolizumab on disease flare (worsening) is unknown, as this was not measured. </p> <p><i>Etanercept or belimumab versus placebo in GPA and MPA</i> </p> <p>Moderate‐certainty evidence indicates that etanercept probably makes little or no difference to disease flare. </p> <p>Low‐certainty evidence suggests that etanercept or belimumab may make little or no difference to: </p> <p>‐ mortality;</p> <p>‐ the disease fully disappearing for at least 24 weeks, or disappearance lasting at least another six months after that; </p> <p>‐ the disease returning strongly;</p> <p>‐ unwanted events or severe/serious unwanted events</p> <p>Evidence of low certainty suggests that etanercept or belimumab may slightly increase chances of people withdrawing from studies due to unwanted events. </p> <p><i>Infliximab versus rituximab, plus steroids and cytotoxic agents (substances that kill cells), in people with GPA that did not respond to other treatments</i> </p> <p>The one study we found was too small to assess the differences between treatments (very low‐certainty evidence). </p> <p><b>What this means</b> </p> <p>Mepolizumab probably reduces the likelihood of the disease returning within a year of treatment, and etanercept probably makes little or no difference to disease flare. We are less certain of the other potential benefits or risks of anti‐cytokine medicines because the evidence is of low or very low certainty. Further research is likely to change the findings of this review. </p> <p><b>How‐up‐to date is this review?</b> </p> <p>The evidence in this Cochrane Review is current to August 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008333-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008333-sec-0111"></div> <h3 class="title" id="CD008333-sec-0112">Implications for practice</h3> <section id="CD008333-sec-0112"> <p>We found only four studies, of which three had major limitations and one was conducted in a small number of patients. There is thus limited evidence for drawing conclusions about the benefit and risk of anti‐cytokine therapy in ANCA‐associated vasculitis. In patients with relapsing or refractory EGPA, compared to placebo, we found moderate‐certainty evidence that mepolizumab probably decreases disease relapse, and low‐certainty evidence that mepolizumab may increase disease remission. There was low‐certainty evidence on the similar frequency of AEs and serious AEs in both groups. The effect of mepolizumab as compared with placebo is uncertain, due to low‐certainty evidence. </p> <p>We found low‐certainty evidence that etanercept/belimumab may increase the probability of withdrawal due to AEs, and low‐certainty evidence that etanercept/belimumab may have little or no impact on durable remission, major relapse and serious AEs. We found moderate‐certainty evidence of no improvement in disease flare. Low‐certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy when compared with standard therapy does not increase or reduce mortality. </p> <p>Due to very low‐certainty evidence for all outcomes, the effects of infliximab, as compared to rituximab, in the management of patients with refractory GPA, is uncertain. </p> </section> <h3 class="title" id="CD008333-sec-0113">Implications for research</h3> <section id="CD008333-sec-0113"> <p>Future research should be adequately powered and should ensure proper adherence to treatment to assess the effects of the intervention on clinically important outcomes in patients with ANCA‐associated vasculitis (AVV). It should also be reported properly, which will enable meaningful conclusions regarding the long‐term benefits and harms of anti‐cytokine targeted therapy. Due to the high heterogeneity of enrolled cases, especially concerning the uneven population of GPA and MPA in <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>, further investigations on belimumab benefits and harms are justified. Due to limited evidence on the safety of mepolizumab, further investigations are justified. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008333-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008333-sec-0008"></div> <div class="table" id="CD008333-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mepolizumab compared to placebo for adults with EGPA ANCA‐associated vasculitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mepolizumab compared to placebo for adults with EGPA ANCA‐associated vasculitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (age 18 years and older) with EGPA ANCA‐associated vasculitis<br/><b>Setting:</b> clinical centres<br/><b>Intervention:</b> mepolizumab (300 mg; 3 separate injections every 4 weeks)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With mepolizumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.39<br/>(0.15 to 372.38) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0%<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/>(0 fewer to 0 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During 52 weeks follow‐up, one death was reported in the mepolizumab group and no deaths in placebo group. </p> <p>The low‐certainty evidence suggests that mepolizumab results in little to no difference in mortality. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission for at least 24 weeks<br/>assessed with: BVAS v.3 of 0 (on a scale from 0 to 63)<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 9.50<br/>(2.30 to 39.21) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9%<br/>(6.8 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0% more<br/>(3.8 more to 112.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests mepolizumab results in a large increase of the probability of accruing at least 24 weeks of remission over a 52‐week period. </p> <p>NNTB 4, 95% CI 3 to 8</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Durable remission within the first 24 weeks sustained until week 52<br/>assessed with: BVAS v.3 of 0 (on a scale from 0 to 63)<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 13.00<br/>(1.75 to 96.33) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.1%<br/>(2.6 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.6% more<br/>(1.1 more to 140.2 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that mepolizumab results in a large increase of the probability of durable remission within the first 24 weeks, sustained until week 52. </p> <p>NNTB 6 95% CI 4 to 13</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease relapse<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/>(0.53 to 0.86) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.0%<br/>(43.6 to 70.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4% fewer<br/>(38.7 fewer to 11.5 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab probably results in a reduction in disease relapse.<br/>NNTB 4, 95% CI 3 to 9 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease flares</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.96 to 1.11) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.9%<br/>(90.4 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8% more<br/>(3.8 fewer to 10.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that mepolizumab does not increase any adverse event.<br/>Number of participants reporting similar rates of any AEs in mepolizumab and placebo group (97% vs 94%). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any serious adverse event<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.67<br/>(0.35 to 1.28) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7%<br/>(9.3 to 33.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7% fewer<br/>(17.2 fewer to 7.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that mepolizumab results in little to no difference in any serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any withdrawals due to AEs<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 2.00<br/>(0.19 to 21.54) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9%<br/>(0.3 to 31.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% more<br/>(1.2 fewer to 30.2 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that mepolizumab does not increase any withdrawals due to AEs.<br/>The study reported similar number of patients withdrawn from mepolizumab and placebo groups due to AEs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ANCA</b> : anti‐neutrophilic cytoplasmic antibodies; <b>CI:</b> Confidence interval; <b>BVAS:</b> Birmingham Vasculitis Activity Score; <b>EGPA:</b> eosinophilic granulomatosis with polyangiitis; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for imprecision: CIs are wide and the number of events was too low to reliably assess optimal information size (OIS); or OIS not met </p> <p><sup>2</sup>Downgraded by one level for imprecision: the number of events was lower than indicated in GRADE guidance </p> <p>AE ‐ adverse event</p> <p>ANCA – antineutrophil cytoplasmic antibody</p> <p>BVAS – Birmingham Vasculitis Activity Score</p> <p>EGPA – eosinophilic granulomatosis with polyangiitis</p> <p>NNTB ‐ number needed to treat for an additional beneficial outcome</p> <p>OR ‐ odds ratio</p> <p>RCT ‐ randomized controlled trial</p> <p>RR ‐ relative risk</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008333-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Active drug (etanercept or belimumab) with standard therapy compared to standard therapy with placebo for adults with GPA ANCA‐associated vasculitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Active drug (etanercept or belimumab) with standard therapy compared to standard therapy with placebo for adults with GPA ANCA‐associated vasculitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study, i.e. 7.7% of total population and not analysed separately)<br/><b>Setting:</b> clinical centres in etanercept study and not reported in belimumab study<br/><b>Intervention:</b> active drug (etanercept: 25 mg twice a week for a median of 25 months or belimumab: 10 mg/kg on days 0, 14, 28 and every 28 days thereafter until 12 months after the last participant was randomised) with standard therapy<br/><b>Comparison:</b> standard therapy with placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With standard therapy and placebo</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With active drug (etanercept or belimumab) with standard therapy</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/>Number of participants: 285<br/>(2 RCTs) </p> <p>WGET 2005 follow‐up: 27 months; BREVAS 2018 follow‐up: approximately up to 4 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Peto OR 2.45<br/>(0.55 to 10.97) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%<br/>(0.8 to 15.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0% more<br/>(0.6 fewer to 13.9 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Five deaths was reported in active drug (etanercept or belimumab) with standard therapy group and two deaths in standard therapy with placebo group. </p> <p>Low‐certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy when compared with standard therapy does not increase/reduce mortality. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission (number of patients with remission)<br/>assessed with: BVAS/WG = 0 </p> <p>WGET 2005 follow‐up: 27 months<br/>Number of participants: 180<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/>(0.89 to 1.07) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.5%<br/>(82.2 to 98.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8% fewer<br/>(10.2 fewer to 6.5 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy when compared with standard therapy with placebo may have little or no effect on remission. However, any effect is likely to be small. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Durable remission<br/>assessed with: BVAS/WG = 0 for ≥ 6 months<br/>follow‐up: 27 months<br/>Number of participants: 174<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.93<br/>(0.77 to 1.11) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.0%<br/>(58 to 83.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3% fewer<br/>(17.3 fewer to 8.3 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐certainty evidence suggests that etanercept added to standard therapy when compared with standard therapy and placebo may have little or no effect on durable remission. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major relapse<br/>assessed with: BVAS (experiencing at least 1 major BVAS item) </p> <p>follow‐up: year 2 week 28<br/>Number of participants: 105<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 2.94<br/>(0.12 to 70.67) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0%<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/>(0 fewer to 0 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐certainty evidence suggests that belimumab added to standard therapy when compared with standard therapy and placebo does not increase/reduce major relapse. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease flare<br/>assessed with: BVAS/WG ‐ increase of at least one point in scale<br/>follow‐up: 27 months<br/>Number of participants: 180<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/>(0.76 to 1.27) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.0%<br/>(43.4 to 72.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1% fewer<br/>(13.7 fewer to 15.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Etanercept added to standard therapy when compared with standard therapy with placebo probably does not reduce disease flare. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event follow‐up: approximately up to 4 years</p> <p>Number of participants: 105<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>RR 1.12</p> <p>(0.97 to 1.29)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>82.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.5%</p> <p>(2.5 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9% more</p> <p>(2,5 fewer to 24 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The low‐certainty evidence suggests that belimumab added to standard therapy when compared with standard therapy with placebo may result in little or no difference in any AE. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe or serious AE (grade 3, 4 or 5)<br/>assessed with: the National Cancer Institute Toxicity Grading Scale </p> <p>WGET 2005 follow‐up: 27 months; BREVAS 2018 follow‐up: approximately up to 4 years<br/>Number of participants: 285<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.80 to 1.27) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.6%<br/>(38 to 60.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/>(9.5 fewer to 12.8 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy when compared with standard therapy with placebo may result in little or no difference in severe or serious AE (grade 3, 4 or 5). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any withdrawals due to AE<br/>assessed with the National Cancer Institute Toxicity Grading Scale </p> <p>WGET 2005 follow‐up: 27 months; BREVAS 2018 follow‐up: approximately up to 4 years<br/>Number of participants: 285<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 2.66<br/>(1.07 to 6.59) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2%<br/>(4.5 to 27.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0% more<br/>(0.3 more to 23.5 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy when compared with standard therapy with placebo results in a slight increase in any withdrawals due to AE. </p> <p>NNTH 15, 95% CI 8 to 100</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ANCA</b> : anti‐neutrophilic cytoplasmic antibodies; <b>CI:</b> Confidence interval;<b>BVAS/WG:</b> Birmingham Vasculitis Activity Score for Wegener's Granulomatosis; <b>GPA:</b> granulomatosis with polyangiitis; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for imprecision: optimal information size (OIS) not achieved; low number of events; confidence intervals very wide or indicating both harm and benefit </p> <p><sup>2</sup>Downgraded by one level due to high risk of selective outcome reporting bias in both studies </p> <p><sup>3</sup>Downgraded by one level for imprecision: OIS criteria are met, but the CIs are very wide; or OIS not achieved, and confidence interval indicates both harm and benefit </p> <p>AE ‐ adverse event</p> <p>ANCA – antineutrophil cytoplasmic antibody</p> <p>BREVAS ‐ Belimumab in Remission of VASculitis</p> <p>BVAS – Birmingham Vasculitis Activity Score</p> <p>BVAS/WG – Birmingham Vasculitis Activity Score for granulomatosis with polyangiitis</p> <p>GPA – granulomatosis with polyangiitis</p> <p>NNTH ‐ number needed to treat for an additional harmful effect</p> <p>OR ‐ odds ratio</p> <p>RCT ‐ randomized controlled trial</p> <p>RR ‐ relative risk</p> <p>WGET ‐ Wegener's Granulomatosis Etanercept Trial</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008333-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Infliximab compared to rituximab for adults with refractory GPA ANCA‐associated vasculitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to rituximab for adults with refractory GPA ANCA‐associated vasculitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> infliximab (3 mg/kg on days 1 and 14, before the response assessment on day 42; further treatment depending on the response)<br/><b>Comparison:</b> rituximab (0.375g/m<sup>2</sup> on days 1, 8, 15 and 22 before the response assessment at month 2; further treatment depending on the response) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With rituximab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With infliximab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/>follow‐up: 12 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.88<br/>(0.05 to 15.51) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.0%<br/>(0.6 to 193.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% fewer<br/>(11.9 fewer to 181.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One death was reported in each group.</p> <p>The evidence is very uncertain about the effect of infliximab when compared to rituximab on mortality. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission<br/>assessed with: BVAS=0<br/>follow‐up: 12 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.44<br/>(0.11 to 1.81) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.0%<br/>(5.5 to 90.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.0% fewer<br/>(44.5 fewer to 40.5 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of infliximab when compared with rituximab on remission at month 12. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Durable remission during additional follow‐up beyond 12 months<br/>follow‐up: mean 30.6 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.22<br/>(0.03 to 1.60) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.0%<br/>(1.5 to 80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.0% fewer<br/>(48.5 fewer to 30 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of infliximab when compared with rituximab on durable remission during additional follow‐up beyond 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease flare/relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>This outcome was not reported in included trial.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>The total number of any AEs was not reported in the study.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe AEs<br/>assessed with: the World Health Organization classification (2003)<br/>follow‐up: 12 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.78<br/>(0.20 to 16.10) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.3%<br/>(2.5 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8% more<br/>(10 fewer to 188.8 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of infliximab when compared with rituximab on any severe AEs. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any withdrawals due to AEs<br/>assessed with: the World Health Organization classification (2003)<br/>follow‐up: 12 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 2.70<br/>(0.13 to 58.24) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0%<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/>(0 fewer to 0 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of infliximab when compared with rituximab on any withdrawals due to AEs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>GPA:</b> granulomatosis with polyangiitis; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to risk of bias – unclear randomisation and concealment, no blinding and unclear selective outcome reporting </p> <p><sup>2</sup>Downgraded by two levels for imprecision: optimal information size (OIS) not met and CI indicates both harm and benefit; and/or low number of events </p> <p>AE ‐ adverse event</p> <p>ANCA – antineutrophil cytoplasmic antibody</p> <p>BVAS – Birmingham Vasculitis Activity Score</p> <p>GPA – granulomatosis with polyangiitis</p> <p>OR ‐ odds ratio</p> <p>RCT ‐ randomized controlled trial</p> <p>RR ‐ relative risk</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008333-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008333-sec-0009"></div> <section id="CD008333-sec-0010"> <h3 class="title" id="CD008333-sec-0010">Description of the condition</h3> <p>Vasculitides are a heterogenous group of rare diseases characterised by inflammation of the vessel wall. Infectious, environmental (e.g. drugs), genetic and other factors are probably involved in the pathogenesis of vasculitis (<a href="./references#CD008333-bbs2-0087" title="McKinneyEF , WillcocksLC , BroeckerV , SmithKGC . The immunopathology of ANCA-associated vasculitis. Seminars in Immunopathology2014;36(4):461-478.">McKinney 2014</a>). The underlying pathology is complex and characteristically involves immune‐mediated inflammation of blood vessel walls, resulting in ischaemic and localised inflammatory injury to tissues in the territory of the affected vessels (<a href="./references#CD008333-bbs2-0072" title="Gonzalez-GayMA , Garcia-PorruaC . Systemic vasculitides. Best Practice &amp; Research in Clinical Rheumatology2002;16(5):833-45.">Gonzalez‐Gay 2002</a>). Disease subtypes follow the Chapel Hill Consensus Conference (CHCC) nomenclature system, which has been in use since 1994. This document categorises vasculitides on the basis of several aetiological and clinical features, including the diameter of the affected vessels (large, medium, small vessel vasculitis). Major advances in our understanding of the vasculitis pathology, including the importance of ANCA status, were among the main reasons for the CHCC 2012 revision. Additionally, disease eponym names were replaced with descriptive names (e.g. granulomatosis with polyangiitis, instead of Wegener’s granulomatosis) (<a href="./references#CD008333-bbs2-0079" title="JennetteJC , FalkRJ , BaconPA , BasuN , CidMC , FerrarioF , et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis &amp; Rheumatism2013;65(1):1-11.">Jeanette 2013</a>). </p> <p>According to this nomenclature, ANCA‐associated vasculitis (AAV) predominantly affects small vessels and consists of three entities: granulomatosis with polyangiitis (GPA; Wegener’s granulomatosis), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA; Churg‐Strauss vasculitis) (<a href="./references#CD008333-bbs2-0089" title="MerkelPA , MattesonEL , Ramirez CurtisM . Overview of and approach to the vasculitides in adults. In: Post TW (editor). UpToDate, Waltham, MA. September 22, 2015.">Merkel 2015</a>). AAV entities are rare diseases with combined prevalence estimated at between 90 and 144 per million, and with annual incidence of around 20 per million (<a href="./references#CD008333-bbs2-0065" title="CotchMF , HoffmanGS , YergDE , KaufmanGI , TargonskiP , KaslowRA . The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis &amp; Rheumatism1996;39(1):87-92.">Cotch 1996</a>; <a href="./references#CD008333-bbs2-0071" title="GibsonA , StampLK , ChapmanPT , O'DonnellJL . The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology2006;45(5):624-8.">Gibson 2006</a>; <a href="./references#CD008333-bbs2-0085" title="MahrA , GuillevinL , PoissonnetM , SegoleneA . Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis &amp; Rheumatism2004;51(1):92-9.">Mahr 2004</a>; <a href="./references#CD008333-bbs2-0098" title="WattsRA , LaneSE , BenthamG , ScottDG . Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis &amp; Rheumatism2000;43(2):414-9.">Watts 2000</a>). </p> <p>The frequency of ANCA‐associated vasculitis seems to be geographically determined. For example, increased incidence of GPA occurs in northern Europe, whereas greater MPA incidence has been reported in southern Europe (<a href="./references#CD008333-bbs2-0081" title="KatsuyamaT , SadaKE , MakinoH . Current concept and epidemiology of systemic vasculitides. Allergology International2014;63(4):505-13.">Katsuyama 2014</a>). Some evidence indicates that the incidence is increasing (<a href="./references#CD008333-bbs2-0098" title="WattsRA , LaneSE , BenthamG , ScottDG . Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis &amp; Rheumatism2000;43(2):414-9.">Watts 2000</a>). Not all AAV conditions have positive ANCA status; this status differs by entity. Approximately 85% to 90% of patients with GPA, 70% of those with MPA and approximately 30% to 40% of patients with EGPA are ANCA‐positive (<a href="./references#CD008333-bbs2-0086" title="MahrA , MoosigF , NeumannT , SzczeklikW , TailléC , VaglioA , et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Current Opinion in Rheumatology2014;26(1):16-23.">Mahr 2014</a>; <a href="./references#CD008333-bbs2-0089" title="MerkelPA , MattesonEL , Ramirez CurtisM . Overview of and approach to the vasculitides in adults. In: Post TW (editor). UpToDate, Waltham, MA. September 22, 2015.">Merkel 2015</a>). </p> <p>If ANCAs are present in AAV, they are most commonly directed against myeloperoxidase (MPO‐ANCA) or proteinase 3 (PR3‐ANCA) (<a href="./references#CD008333-bbs2-0074" title="HarperL , RadfordD , PlantT . IgG from myeloperoxidase–antineutrophil cytoplasmic antibody–positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3–antineutrophil cytoplasmic antibody–positive patients. Arthritis &amp; Rheumatology2001;44(4):921-30.">Harper 2001</a>) and can help in establishing the diagnosis. Increasing evidence suggests that ANCA status determines the disease course and clinical manifestations (<a href="./references#CD008333-bbs2-0066" title="CottinV , BelE , BotteroP , DalhoffK , HumbertM , LazorR , et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157 patients by the Groupe d'Etudes et de Recherchesur les Maladies Orphelines Pulmonaires and the European Respiratory SocietyTaskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunity Reviews2017;16(1):1-9.">Cottin 2017</a>). </p> </section> <section id="CD008333-sec-0011"> <h3 class="title" id="CD008333-sec-0011">Description of the intervention</h3> <p>Treatment recommended for AAV depends on disease severity; induction therapy based on glucocorticosteroids and cyclophosphamide or rituximab is indicated for patients with organ‐threatening disease, particularly of the lungs, kidneys and the nervous system; and glucocorticosteroids and methotrexate or mycophenolate mofetil for those with non‐organ‐threatening AAV (<a href="./references#CD008333-bbs2-0099" title="YatesM , WattsRA , BajemaIM , CidMC , CrestaniB , HauserT , et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of Rheumatic Diseases2016;75(9):1583-94.">Yates 2016</a>). Cyclophosphamide, which was introduced in the 1970s by Hoffman and Fauci (<a href="./references#CD008333-bbs2-0080" title="KameshL , HarperL , SavageCOS . ANCA-positive vasculitis. Journal of the American Society of Nephrology2002;13:1953-60.">Kamesh 2002</a>), is a potent, cytotoxic immunosuppressive agent that has dramatically improved survival among patients with some forms of vasculitides. The combination of cyclophosphamide and prednisolone has become the gold standard for treatment of patients with active systemic vasculitis but it is associated with serious adverse effects, including neutropenia, opportunistic infection, premature menopause and increased rates of cancer, most notably, cancer of the bladder (<a href="./references#CD008333-bbs2-0068" title="FauciAS , HaynesBF , KatzP , WolffSM . Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Annals of Internal Medicine1983;98:76-85.">Fauci 1983</a>; <a href="./references#CD008333-bbs2-0080" title="KameshL , HarperL , SavageCOS . ANCA-positive vasculitis. Journal of the American Society of Nephrology2002;13:1953-60.">Kamesh 2002</a>). Prolonged follow‐up of patients who have received cyclophosphamide reveals increasing over time dose‐dependent rates of bladder cancer (<a href="./references#CD008333-bbs2-0083" title="KnightA , AsklingJ , GranathF , SparenP , EkbomA . Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Annals of the Rheumatic Diseases2004;63(10):1307-11.">Knight 2004</a>). To overcome these treatment‐related toxicities, strategies for introducing less toxic immunosuppressive agents (e.g. methotrexate or azathioprine after induction therapy with a series of cyclophosphamide infusions) have been used with moderate success (<a href="./references#CD008333-bbs2-0078" title="JayneD , RasmussenN , AndrassyK , BaconP , TervaertJWC , DadonieneJ , et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. New England Journal of Medicine2003;349(1):36-44.">Jayne 2003</a>). However, there remains an unmet need for more effective and less toxic treatments for patients in induction and remission phases of vasculitides. Recently, biological immunotherapies capable of specifically targeting and neutralising cytokine mediators of the inflammatory response have entered clinical practice for a variety of immune‐mediated inflammatory diseases. Among biological therapies, treatment options include anti‐tumour necrosis factor (TNF) agents (infliximab, etanercept, adalimumab) or rituximab, which belongs to the group of anti‐CD20 monoclonal antibodies (<a href="./references#CD008333-bbs2-0080" title="KameshL , HarperL , SavageCOS . ANCA-positive vasculitis. Journal of the American Society of Nephrology2002;13:1953-60.">Kamesh 2002</a>, <a href="./references#CD008333-bbs2-0095" title="Silva-FernándezL , LozaE , Martínez-TaboadaVM , BlancoR , Rúa-FigueroaI , Pego-ReigosaJM , et al. Biological therapy for systemic vasculitis: a systematic review. Seminars in Arthritis and Rheumatism2014;43(4):542-57.">Silva‐Fernández 2014</a>). Another Cochrane Review, now in development, is assessing the benefit of rituximab (<a href="./references#CD008333-bbs2-0092" title="RimintonS . Lymphocyte directed biologic therapies for primary systemic necrotizing vasculitis (registered title). Available from:cochrane.org/title/lymphocyte-directed-biologic-therapies-for-primary-systemic-necrotizing-vasculitis 2008 (Accessed 23 March 2017).">Riminton 2008</a>). Molecules other than anti‐TNF agents and rituximab, such as abatacept, mepolizumab (an anti‐IL5 antibody) and alemtuzumab (a humanised monoclonal anti‐CD52 antibody) have been used in refractory cases of AAV. These agents hold promise for safer, more effective targeted intervention, and studies in ANCA‐associated vasculitis have commenced. Mepolizumab has been used in a pilot study on EGPA to allow decreasing steroid doses (<a href="./references#CD008333-bbs2-0082" title="KimS , MarigowdaG , OrenE , IsraelE , WechslerME . Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. Journal of Allergy and Clinical Immunology2010;125(6):1336-43.">Kim 2010</a>) and has been fully assessed in a randomised trial called MIRRA (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>). </p> </section> <section id="CD008333-sec-0012"> <h3 class="title" id="CD008333-sec-0012">How the intervention might work</h3> <p>Consideration of the mechanisms underlying chronic inflammatory disease such as vasculitis has revealed a primary, pivotal role of cytokines. Cytokines comprise a diverse family of small molecule mediators of intercellular communication that have essential roles in mobilisation of the inflammatory response. Tumour necrosis factor‐alpha (TNF‐alpha), as one example, has a central role in the downstream production of both pro‐inflammatory and anti‐inflammatory cytokines, which appear to be maintained at a dysfunctional equilibrium in chronic inflammatory disease. TNF‐alpha is among the first of the cytokines to rise in response to bacterial infection (<a href="./references#CD008333-bbs2-0069" title="FeldmannM , PuseyCD . Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. Journal of the American Society of Nephrology2006;17(5):1243-52.">Feldmann 2006</a>). Studies have shown that TNF‐alpha plays a central role in mouse models of renal vasculitis, and the treatment of the affected mice with anti‐TNF‐alpha has improved their outcomes (<a href="./references#CD008333-bbs2-0069" title="FeldmannM , PuseyCD . Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. Journal of the American Society of Nephrology2006;17(5):1243-52.">Feldmann 2006</a>). In another chronic immune‐mediated inflammatory disease, rheumatoid arthritis (RA), the inhibition of TNF‐alpha activity by both monoclonal antibodies and a soluble receptor decoy has been shown to be effective in the management of signs, symptoms and radiographic progression (<a href="./references#CD008333-bbs2-0063" title="ChenYF , JobanputraP , BartonP , JowettS , BryanS , ClarkW , et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technology Assessment2006;10(42):1-229.">Chen 2006</a>). Another anti‐cytokine therapy, namely, interleukin‐1 receptor antagonist (IL‐1RA; anakinra), has been shown to provide benefit for patients with RA (<a href="./references#CD008333-bbs2-0064" title="CohenS , HurdE , CushJ , SchiffM , WeinblattME , MorelandLW , et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial [see comment]. Arthritis &amp; Rheumatism2002;46(3):614-24.">Cohen 2002</a>). Future directions and potential therapeutic options include interleukin (IL)‐6 antagonist (B‐cell stimulatory factor‐2; BSF‐2). Several studies have reported that tocilizumab (anti‐interleukin‐6 agent) was successfully used for some systemic diseases such as RA, and its benefit in RA is well established (<a href="./references#CD008333-bbs2-0061" title="BertiA , CavalliG , CampochiaroC , GuglielmiB , BaldisseraE , CappioS , et al. Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab. Seminars in Arthritis and Rheumatism 2015 Aug;45(1):48-54.">Berli 2015</a>). Inhibition of pro‐inflammatory cytokines has therefore emerged as an attractive prospect for the management of ANCA‐associated vasculitis. </p> </section> <section id="CD008333-sec-0013"> <h3 class="title" id="CD008333-sec-0013">Why it is important to do this review</h3> <p>ANCA‐associated vasculitis comprises a group of rare systemic diseases. Effective treatment is important because progression of these diseases may be dramatic. Physicians who are responsible for the care of these patients are confronted with an important dilemma: whether to employ conventional cytotoxic immunosuppressive strategies with unsatisfactory primary resistance, relapse and drug‐induced adverse events (AEs); or whether to employ novel biological anti‐cytokine therapies with the potential for greater benefit and tolerability. Further uncertainty is raised by the use of combinations of conventional and novel therapies, and by a rapidly evolving evidence base. Anti‐cytokine therapies represent another treatment option. Systematic reviews can provide some answers. </p> <p>Use of anti‐cytokine therapy has been reported in patients with ANCA‐associated vasculitides (e.g. <a href="./references#CD008333-bbs2-0060" title="Al-BishriJ , le RicheN , PopeJE . Refractory polyarteritis nodosa successfully treated with infliximab. Journal of Rheumatology2005;32(7):1371-3.">Al‐Bishri 2005</a>; <a href="./references#CD008333-bbs2-0084" title="LamprechtP , VoswinkelJ , LilienthalT , NolleB , HellerM , GrossWL , et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology2002;41(11):1303-7.">Lamprecht 2002</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>), but no Cochrane systematic review has focused on this type of treatment in this group of patients. </p> <p>We conducted this review according to the guidelines provided by the Cochrane Musculoskeletal Group Editorial Board (<a href="./references#CD008333-bbs2-0070" title="GhogomuEA , MaxwellLJ , BuchbinderR , RaderT , Pardo PardoJ , et al. Updated method guidelines for Cochrane musculoskeletal group systematic reviews and metaanalyses. Journal of Rheumatology2014;41(2):194-205.">Ghogomu 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008333-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008333-sec-0014"></div> <p>To assess the benefits and harms of anti‐cytokine targeted therapy for adults with ANCA‐associated vasculitis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008333-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008333-sec-0015"></div> <section id="CD008333-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008333-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs) and controlled clinical trials (CCTs) for inclusion in this review. We planned to include studies reported as abstracts without data in the 'Studies awaiting assessment' category and to contact study authors for additional detailed data, but we have not come across such a study. However, we came across several studies that were registered and completed but did not report their results. In such cases, we attempted to contact the authors for additional information. We applied no restrictions on length of follow‐up or language. </p> </section> <section id="CD008333-sec-0018"> <h4 class="title">Types of participants</h4> <p>We restricted inclusion in this review to trials that met the following criteria.</p> <p> <ul id="CD008333-list-0001"> <li> <p>All studies primarily concerning ANCA‐associated vasculitis in adult populations (18 years of age or older). </p> </li> <li> <p>Specific confirmed diagnoses of participants including GPA, EGPA and MPA) .</p> </li> </ul> </p> <p>We excluded patients with other types of vasculitides.</p> </section> <section id="CD008333-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We considered all randomised controlled comparisons of specifically targeted anti‐cytokine therapy versus placebo, standard therapy or another modality. We considered various types and dosages of anti‐cytokine therapy. </p> <p>We considered all available anti‐cytokine therapies, such as TNF‐alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), inhibitors of soluble B‐lymphocyte stimulator (BLyS) cytokine (belimumab), interleukin receptor antagonists and interleukin inhibitors (anakinra, basiliximab, benralizumab, brodalumab, canakinumab, clazakizumab, daclizumab, dupilumab, ixekizumab, lebrikizumab, mepolizumab, olokizumab, pitrakinra, reslizumab, rilonacept, sarilumab, secukinumab, siltuximab, sirukumab, tocilizumab, tralokinumab, ustekinumab), as well as anti‐cytokine therapies that will be developed in the future<i>.</i> We did not include interventions that were not specifically directed at cytokines but that may nevertheless alter cytokine expression or function (e.g. corticosteroids). </p> </section> <section id="CD008333-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008333-sec-0021"> <h5 class="title">Major outcomes</h5> <p>Major benefit outcomes included:</p> <p> <ul id="CD008333-list-0002"> <li> <p>mortality;</p> </li> <li> <p>remission (as defined by study authors, typically as complete absence of disease activity (<a href="./references#CD008333-bbs2-0088" title="MerkelPA , AydinSZ , BoersM , DireskeneliH , HerlynK , SeoP , et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. Journal of Rheumatology2011;38(7):1480-6.">Merkel 2011</a>) measured by Birmingham Vasculitis Activity Score (BVAS), BVAS/ WG (for GPA) or BVAS v3); </p> </li> <li> <p>durable remission (defined according to BVAS, BVAS WG or BVAS v3 for at least six months) (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>); and </p> </li> <li> <p>disease flare/relapse (as defined by study authors, typically as increased disease activity from a previous low or absent state) (<a href="./references#CD008333-bbs2-0088" title="MerkelPA , AydinSZ , BoersM , DireskeneliH , HerlynK , SeoP , et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. Journal of Rheumatology2011;38(7):1480-6.">Merkel 2011</a>). </p> </li> </ul> </p> <p>Major harms outcomes included:</p> <p> <ul id="CD008333-list-0003"> <li> <p>total AEs;</p> </li> <li> <p>serious AEs; and</p> </li> <li> <p>withdrawals due to AEs.</p> </li> </ul> </p> </section> <section id="CD008333-sec-0022"> <h5 class="title">Minor outcomes</h5> <p>Minor outcomes included:</p> <p> <ul id="CD008333-list-0004"> <li> <p>treatment response (defined as quantifiable improvement in disease activity (<a href="./references#CD008333-bbs2-0088" title="MerkelPA , AydinSZ , BoersM , DireskeneliH , HerlynK , SeoP , et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. Journal of Rheumatology2011;38(7):1480-6.">Merkel 2011</a>) as assessed by BVAS, BVAS WG or BVAS v3 with cut‐off point as defined by study authors); </p> </li> <li> <p>health‐related quality of life (as assessed by Short Form (SF)‐36 or other health‐related quality of life measures, including those specific to AAV); </p> </li> <li> <p>control of asthma/sinonasal disease (as defined by study authors); and</p> </li> <li> <p>disease damage according to the Vasculitis Damage Index (VDI), the AAV Index of Damage (AVID) or other validated disease damage scores accepted by Outcome Measures in Rheumatology (OMERACT). </p> </li> </ul> </p> </section> <section id="CD008333-sec-0023"> <h5 class="title">Time points</h5> <p>We planned to collect data reported at six months,12 months and more than 12 months, as well as during active treatment and after treatment cessation. Ultimately, we included all time points reported in the studies. </p> </section> </section> </section> <section id="CD008333-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched all databases from their inception to the 16 August 2019, and we imposed no restriction on language and date of publication. </p> <section id="CD008333-sec-0025"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases and sources to identify studies (all searches performed on 16 August 2019). </p> <p> <ul id="CD008333-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (2019, Issue 7).</p> </li> <li> <p>MEDLINE (OVID).</p> </li> <li> <p>Embase (OVID).</p> </li> </ul> </p> <p>We searched the following ongoing trial registries (all searches performed on 28 August 2019). </p> <p> <ul id="CD008333-list-0006"> <li> <p>ClinicalTrials.gov (www.ClinicalTrials.gov).</p> </li> <li> <p>European Trials Register (www.clinicaltrialsregister.eu).</p> </li> <li> <p>ISRCTN (International Standard Randomised Controlled Trial Number Registry; www.isrctn.com).</p> </li> <li> <p>WHO (World Health Organization) trials portal (www.who.int/ictrp/en).</p> </li> </ul> </p> <p>For the assessments of AEs, we searched the web sites of regulatory agencies (all searches performed on 3 September 2019), such as the US Food and Drug Administration‐MedWatch (www.fda.gov/Safety/MedWatch/default.htm), the European Medicines Evaluation Agency (www.emea.europa.eu), the Australian Adverse Drug Reactions Bulletin (www.tga.gov.au/adr/aadrb.htm) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) for pharmacovigilance and drug safety updates (www.mhra.gov.uk). We searched each database using basic terms, e.g. ANCA vasculitis, etanercept, mepolizumab, infliximab and belimumab. </p> <p>See <a href="./appendices#CD008333-sec-0117">Appendix 1</a> for the MEDLINE search strategy, Embase search strategy and CENTRAL search strategy. </p> </section> <section id="CD008333-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We searched relevant manufacturers' web sites for trial information. When we identified unpublished trials, we sought contact with relevant authors for further information. We checked www.clinicaltrialresults.org and the web sites of regulatory agencies such as the US Food and Drug Administration‐MedWatch (www.fda.gov) and the European Medicines Evaluation Agency (www.emea.europa.eu) for unpublished data. </p> <p>We searched for errata and retractions from included studies published in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed) and planned to report in the review the date this was done, but no such cases occurred. </p> </section> </section> <section id="CD008333-sec-0027"> <h3 class="title" id="CD008333-sec-0027">Data collection and analysis</h3> <section id="CD008333-sec-0028"> <h4 class="title">Selection of studies</h4> <p>For study selection, we used Covidence (www.covidence.org), a new tool recommended by Cochrane to facilitate production of systematic reviews. Two review authors (JZ, MK, TMM, MMB, JJ or WS) independently screened titles and abstracts of articles identified by the search to determine their potential for inclusion in the review and coded them as 'yes/maybe' (eligible or potentially eligible/unclear) or 'no.' We retrieved full‐text study reports/publications, and two review authors (JZ, MK, TMM, MMB, JJ or WS) independently screened full texts to identify studies for inclusion and recorded reasons for exclusion of ineligible studies. We resolved disagreements through discussion, or, if required, we consulted a third review author (WS or MMB). We identified and excluded duplicates and collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) flow diagram (PRISMA Group) (<a href="./references#CD008333-bbs2-0090" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ2009;21(339):b2535. [DOI: 0.1136/bmj.b2535]">Moher 2009</a>) and 'Characteristics of excluded studies' tables. </p> </section> <section id="CD008333-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>If Covidence allowed for adjustment of data extraction forms, we planned to use this tool for data extraction; otherwise, we planned to prepare a data extraction form in Microsoft Excel. Ultimately, we extracted the data to the forms prepared in Microsoft Excel. We recorded study characteristics and outcome data on a data collection form that was piloted on at least one study in the review. We planned that the extraction process would be carried out by one review author and spot‐checked by another one, but to improve the quality of our review we decided to proceed with independent extraction by two review authors (JZ, JJ or MK). We extracted the following study characteristics from the included studies. </p> <p> <ul id="CD008333-list-0007"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study setting, withdrawals, date of study. </p> </li> <li> <p>Participants: number of participants included in the study and number of participants in each group, number of participants who completed follow‐up, mean age, age range, sex, disease duration, severity of condition, diagnostic criteria, important ANCA vasculitides‐specific baseline data such as prior treatment, presence of comorbidity. </p> </li> <li> <p>Interventions: intervention, comparison, dosing regimen, route of administration, concomitant use of steroids, excluded medications, duration of treatment. </p> </li> <li> <p>Outcomes: major and minor outcomes specified and collected, time points reported.</p> </li> <li> <p>Characteristics of trial design as outlined in the 'Assessment of risk of bias in included trials' section. </p> </li> <li> <p>Notes: funding for trial, notable declarations of interest of trial authors.</p> </li> </ul> </p> <p>Each extraction was checked for accuracy against the trial report by an additional review author (MMB, TMM or WS). </p> <p>Two review authors (JZ, JJ or MK) independently extracted outcome data from the included studies. We extracted numbers of events and participants per treatment group for dichotomous outcomes; and means, standard deviations and numbers of participants per treatment group for continuous outcomes. If reported, we extracted confidence intervals and P values. We planned to note in the 'Characteristics of included studies' table if outcome data were not reported in a useable way and if data were transformed or estimated from a graph. We resolved disagreements by reaching consensus or by involving a third review author (MMB, TMM or WS). One review author (MK, JZ or JJ) transferred data into the Review Manager (<a href="./references#CD008333-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) file. We double‐checked whether that data were entered correctly by comparing data presented in the systematic review with the study reports. </p> <p>We used results from an intention‐to‐treat analysis, if possible. If a study reported multiple time point measurements, we extracted all time point values and used final values data for analysis. For continuous outcomes, if both final values and change from baseline values were reported for the same outcome, we planned to extract both values and use change values for primary analysis. If investigators reported both adjusted and unadjusted values for the same outcome, we planned to extract both estimates and use adjusted values with the maximum number of covariates. </p> </section> <section id="CD008333-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two pairs of review authors (JZ, MK, JJ, MMB, TMM or WS) independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008333-bbs2-0075" title="HigginsJPT , AltmanDG , Sterne JAC editor(s). Chapter 8. Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane.handbook.org.">Higgins 2011a</a>). We resolved disagreements by discussion or by consultation with another review author (WS or MMB). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD008333-list-0008"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias (such as bias related to issues of study design, baseline imbalance, stopping early for benefit, influence of interim results on study conduct, inappropriate administration of co‐interventions and selective reporting of subgroups). </p> </li> </ul> </p> <p>We graded each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised the risk of bias judgements per outcomes within a study and per outcomes across studies. </p> <p>When we obtained information on risk of bias related to unpublished data or correspondence with a trialist, we planned to note this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for studies that contributed to that outcome. </p> <p>We presented figures generated by the 'risk of bias' tool to provide summary assessments of the risk of bias. </p> <p>We considered a study to have low risk of bias if we judged it to be at low risk in all domains for each outcome; otherwise, we considered the study to have a high risk of bias. </p> </section> <section id="CD008333-sec-0031"> <h4 class="title">Assessment of bias in conducting the systematic review</h4> <p>We conducted the review according to the published protocol and reported deviations from it in the 'Differences between protocol and review' section of the systematic review. </p> </section> <section id="CD008333-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as risk ratios (RRs) or Peto odds ratios (OR) when the outcome was a rare event (approximately &lt; 10%) and used 95% confidence intervals (CIs)<i>.</i> We planned to analyse continuous data as mean differences (MDs) or standardised mean differences (SMDs), depending on whether the same scale was used to measure the outcome, and 95% CIs. We planned to enter data presented as a scale with a consistent direction of effect across studies. </p> <p>We planned to back‐translate SMD to a typical scale (e.g. BVAS) by multiplying the SMD by a typical among‐person standard deviation (e.g. standard deviation of the control group at baseline from the most representative trial) (as per Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008333-bbs2-0094" title="SchünemannH , OxmanAD , VistGE , HigginsJBT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12. Interpreting results and drawing conclusions.In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from handbook.cochrane.org.">Schünemann 2011b</a>)). </p> <p>If results were reported only as mean differences with standard errors (SEs) or 95% CIs, we planned to pool them using the generic inverse variance method available in RevMan5. </p> <p>We planned to analyse time‐to‐event data as hazard ratios (HR).</p> <p>In the 'Effects of intervention' section under 'Results' and in the 'Comments' column of the 'Summary of findings' table, we planned to provide the absolute percentage difference, the relative percentage change from baseline and the number needed to treat for an additional beneficial outcome (NNTB). We provided the NNTB only when the outcome showed a statistically significant difference. </p> <p>For dichotomous outcomes, such as serious AEs, we planned to calculate the NNTB/number needed to treat for an additional harmful effect (NNTH) from the control group event rate and the risk difference (RD) using the Visual Rx NNT calculator (<a href="./references#CD008333-bbs2-0062" title="Visual Rx. Version 3. Dr. Christopher Cates EBM web site, 2008. Available at nntonline.net.">Cates 2008</a>). When this was not possible, we used RD and 95% CI calculated in RevMan to calculate NNTB with 100/RD formula. We planned to calculate the NNTB/NNTH for continuous measures using the Wells calculator (available at the CMSG Editorial Office; musculoskeletal.cochrane.org). </p> <p>For dichotomous outcomes, we calculated the absolute RD using the RD statistic in RevMan (<a href="./references#CD008333-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) and expressed the result as a percentage. For continuous outcomes, we planned to calculate the absolute benefit as improvement in the intervention group minus improvement in the control group, in original units, and express this as a percentage. </p> <p>We calculated the relative percentage change for dichotomous data as the risk ratio ‐ 1 and expressed this as a percentage. For continuous outcomes, we planned to calculate the relative difference in change from baseline as the absolute benefit divided by the baseline mean of the control group. </p> </section> <section id="CD008333-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>When multiple trial arms were reported in a single trial, we planned to include only relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we planned to halve the control group to avoid double‐counting. </p> <p>We did not expect to find cross over studies or cluster RCTs but had we done so, we would have followed the guidance in chapter 16 of the Cochrane Handbook (<a href="./references#CD008333-bbs2-0076" title="HigginsJPT , DeeksJJ , Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011b</a>). </p> </section> <section id="CD008333-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study was identified as abstract only, or when data were not available for all participants). When this was not possible, and missing data were thought to introduce serious bias, we planned to explore the impact of including such studies in the overall assessment of results by performing a sensitivity analysis. We planned to clearly describe assumptions and imputations required to handle missing data and explore the effect of imputation by performing sensitivity analyses. In all analyses, we included the numbers of participants reported by the authors for particular outcome and we performed sensitivity analyses in the case of studies with missing data. </p> <p>For dichotomous outcomes (e.g. number of withdrawals due to AEs), we planned to calculate the withdrawal rate by using the number of participants randomised in the group as the denominator. </p> <p>For continuous outcomes (e.g. mean change in pain score), we planned to calculate the mean MD or the SMD by using the number of participants analysed at that time point. If the number of participants analysed was not presented for each time point, we planned to use the number of randomised participants in each group at baseline. </p> <p>Where possible, we planned to compute missing SDs from other statistics such as SEs, CIs or P values, according to the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008333-bbs2-0077" title="HigginsJPT , Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).">Higgins 2011c</a>). If standard deviations could not be calculated, we planned to impute them (e.g. from other studies in the meta‐analysis) following the advice of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008333-bbs2-0077" title="HigginsJPT , Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).">Higgins 2011c</a>)<i>.</i> </p> </section> <section id="CD008333-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the clinical and methodological diversity of the included studies, in terms of participants, interventions, outcomes and study characteristics, to determine whether meta‐analyses were appropriate. We planned to do this by observing data derived from data extraction tables. We planned to assess statistical heterogeneity by visually inspecting forest plots to look for obvious differences in results among studies, and by using I² and Chi² statistical tests. </p> <p>The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008333-bbs2-0067" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>) advises that an I² value from 0% to 40% might not represent important heterogeneity; a value from 30% to 60% may represent 'moderate' heterogeneity; a value from 50% to 90% may represent 'substantial' heterogeneity; and a value from 75% to 100% represents 'considerable' heterogeneity. As noted in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, we kept in mind that the importance of I² depends on the magnitude and direction of effects, and on strength of the evidence for heterogeneity. </p> <p>We interpreted the Chi² test with a P value ≤ 0.10 as evidence of statistical heterogeneity.</p> <p>If we identified substantial heterogeneity, we planned to report this and investigate possible causes by following the recommendations provided in Section 9.6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008333-bbs2-0067" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). </p> </section> <section id="CD008333-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>If possible, we planned to create and examine a funnel plot to explore possible small study biases. In interpreting funnel plots, we planned to examine different possible reasons for funnel plot asymmetry, as outlined in Section 10.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and planned to relate this to review results. If we were able to pool more than 10 trials, we planned to undertake formal statistical tests to investigate funnel plot asymmetry in accordance with the recommendations provided in Section 10.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008333-bbs2-0097" title="SterneJAC , EggerM , Moher D editor(s). Chapter 10. Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Sterne 2011</a>). </p> <p>To assess outcome reporting bias, we checked trial protocols against published reports. For studies published after 1 July 2005, we searched the International Clinical Trials Registry Platform of the World Health Organization (apps.who.int/trialssearch) for the <i>a priori</i> trial protocol. We compared the available protocols with the final results to evaluate whether selective reporting of outcomes occurred. </p> </section> <section id="CD008333-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake meta‐analysis only when this is meaningful (i.e. when treatments, participants and the underlying clinical question are similar enough for pooling to make sense). For the main analyses, we planned to pool results for the longest follow‐up point available. </p> <p>We planned to use a random‐effects model and planned to perform a sensitivity analysis based on the fixed‐effect model. However, our analyses included either single studies presented on the forest plots, or there was no statistical heterogeneity. Therefore, sensitivity analysis with a fixed‐effect model would not have been meaningful. </p> <p>We planned to restrict the primary analysis of self‐reported outcomes in this review to trials at low risk of detection and selection bias. However, there was only one such trial. </p> </section> <section id="CD008333-sec-0038"> <h4 class="title">'Summary of findings' table</h4> <p>We created a 'Summary of findings' (SoF) table using the following outcomes: mortality, remission, durable remission, disease flare/relapse, total AEs, serious AEs and withdrawals due to AEs. The first SoF table presents the comparison of mepolizumab to placebo for adult patients with EGPA ANCA‐associated vasculitis, followed by the SoF table with comparison of active drug (etanercept or belimumab) and standard therapy with standard therapy and placebo in adult patients with GPA ANCA‐associated vasculitis and SoF table with comparison of infliximab with rituximab in adult patients with refractory GPA ANCA‐associated vasculitis. </p> <p>Two review authors (JJ and MK) independently assessed the certainty of the evidence. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of a body of evidence as it relates to studies that contribute data to meta‐analyses for prespecified outcomes. We used methods and recommendations described in Sections 8.5 and 8.7, in Chapter 11 and in Chapter 13, Section 13.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008333-bbs2-0075" title="HigginsJPT , AltmanDG , Sterne JAC editor(s). Chapter 8. Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane.handbook.org.">Higgins 2011a</a>; <a href="./references#CD008333-bbs2-0093" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11. Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011a</a>; <a href="./references#CD008333-bbs2-0094" title="SchünemannH , OxmanAD , VistGE , HigginsJBT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12. Interpreting results and drawing conclusions.In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from handbook.cochrane.org.">Schünemann 2011b</a>). We used GRADEpro software to prepare SoF tables (<a href="./references#CD008333-bbs2-0073" title="McMaster University (developed by Evidence Prime, Inc.)GRADEpro GDT. Version accessed 13 June 2018. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>). We justified all decisions to downgrade or upgrade the certainty of studies by using footnotes, and we provided comments to aid the reader's understanding of the review when necessary. </p> <p>In the 'What happens' column of the SoF table, we provided the absolute percentage difference, the relative percentage change from baseline and the NNTB or the NNTH (but only when the outcome showed a statistically significant difference). </p> </section> <section id="CD008333-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If possible, we planned to carry out the following subgroup analyses.</p> <p> <ul id="CD008333-list-0009"> <li> <p>Newly diagnosed or relapsing ‐ as treatment effects may differ in participants receiving treatment for the first time and those receiving repeated treatment. </p> </li> <li> <p>Different dosage regimens ‐ different doses may show different treatment effects.</p> </li> <li> <p>Duration of treatment ‐ duration of treatment may also influence the results.</p> </li> <li> <p>Type of AAV.</p> </li> <li> <p>ANCA status.</p> </li> </ul> </p> <p>We planned to use the following outcomes in subgroup analyses.</p> <p> <ul id="CD008333-list-0010"> <li> <p>Remission.</p> </li> <li> <p>Total AEs.</p> </li> </ul> </p> <p>We planned to use the formal test for subgroup interactions in Review Manager (<a href="./references#CD008333-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) and apply caution in interpreting subgroup analyses, as advised in Section 9.6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008333-bbs2-0067" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). We planned to compare the magnitude of effects between subgroups by assessing the overlap of confidence intervals of the summary as estimated. Non‐overlap of confidence intervals indicates statistical significance. </p> <p>Since the included studies recruited participants with GPA/MPA only or with EGPA only (relapsing or refractory) we decided to summarise the results separately in the population groups (GPA and EGPA) due to their clinical heterogeneity, as combining them would not be clinically meaningful. We did not have enough studies to carry out other subgroup analyses, therefore, we provided the results in subgroups presented by the authors of the analysed studies, if there was stratification for that characteristic at randomisation. </p> </section> <section id="CD008333-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analyses.</p> <p> <ul id="CD008333-list-0011"> <li> <p>Effect of assessing study risk of bias ‐ as adequate allocation concealment and outcome assessor blinding. </p> </li> <li> <p>Effect of imputing missing data.</p> </li> <li> <p>Effect of including different types of data (i.e. instead of change value, final value for continuous outcomes; instead of adjusted value, unadjusted value). </p> </li> </ul> </p> <p>However, only one study reported excluding participants from analysis (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>) and only in the control group. We repeated the analyses that included this study in the scope of the outcomes for the excluded participants, with the assumption that the participants missing in the control group had the best possible outcome. </p> <p>Since we had planned to perform analyses across all AAV and based on clinical heterogeneity, we decided to pool the data separately for each type of AAV. We performed sensitivity analysis by pooling the different AAV types together for the outcomes for which we had data from more than one study. </p> </section> <section id="CD008333-sec-0041"> <h4 class="title">Interpreting results and reaching conclusions</h4> <p>We followed the guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (see Chapter 12) (<a href="./references#CD008333-bbs2-0094" title="SchünemannH , OxmanAD , VistGE , HigginsJBT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12. Interpreting results and drawing conclusions.In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from handbook.cochrane.org.">Schünemann 2011b</a>) when interpreting results, and we were aware of distinguishing the lack of evidence of effect from the lack of effect. We based our conclusions only on findings from the quantitative or narrative synthesis of the studies included in the studies used in this review. We avoided making recommendations for practice, and our implications for research suggest priorities for future studies while outlining the remaining uncertainties in this area. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008333-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008333-sec-0042"></div> <section id="CD008333-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD008333-sec-0044"> <h4 class="title">Results of the search</h4> <p>We performed our final searches on 16 August 2019. After removing duplicates, we identified 3023 records. We searched trial registries on 28 August 2019 and found 1835 additional records (<a href="#CD008333-fig-0001">Figure 1</a>). Of those records, we retrieved 73 and reviewed them in full text. We excluded papers due to wrong study design (43 papers) or wrong intervention (three papers). We excluded two studies that were withdrawn and stopped by the sponsor because they did not enrol any participants (<a href="./references#CD008333-bbs2-0007" title="BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (BIANCA-SC). Available from: https://clinicaltrials.gov/ct2/show/NCT015988572012. ">BIANCA‐SC</a>, <a href="./references#CD008333-bbs2-0012" title="Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis. Clinicaltrials.gov February 23, 2017. [https://www.clinicaltrials.gov/ct2/show/NCT01275287?id=NCT01275287&amp;rank=1]">Eculizumab 2011</a>) and thus published no results. We identified three studies that still await assessment, as there was insufficient information in the databases. Two of them were closed without being completed (<a href="./references#CD008333-bbs2-0054" title="NCT00001901. Phase I/II Trial of TNFR:Fc (Etanercept) in Patients With Wegener's Granulomatosis. clinicaltrials.gov/ct2/show/NCT00001901 (first received 4 November 1999). ">NIAID 1999</a>, <a href="./references#CD008333-bbs2-0055" title="NCT00040248. A Randomized Trial Examining the Use of Daclizumab in Wegener's Granulomatosis. clinicaltrials.gov/ct2/show/NCT00040248 (first received 24 June 2002). ">NIAID 2002</a>); one was terminated due to slow recruitment, and posted no results (<a href="./references#CD008333-bbs2-0053" title="NCT00482066. A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis. clinicaltrials.gov/ct2/show/NCT00482066 (first received 4 June 2007). ">ABAVAS 2008</a>). </p> <div class="figure" id="CD008333-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008333-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Searching trials registries, we identified four ongoing studies (<a href="./references#CD008333-bbs2-0057" title="NCT02108860. Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE). clinicaltrials.gov/ct2/show/NCT02108860 (first received 9 April 2014). ">ABROGATE</a>; <a href="./references#CD008333-bbs2-0058" title="GopaluniS , GoymerD , McClureM , CahillH , BroadhurstE , Smith, R, et al. Alemtuzumab for relapsing and refractory primary systemic vasculitis - A trial of efficacy and safety (aleviate): A randomised open-label phase ii clinical trial. In: Rheumatology. Vol. 58 Suppl 2. 2019:kez063.026. NCT01405807. Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy. clinicaltrials.gov/ct2/show/NCT01405807?id=NCT01405807&amp;rank=1 (first received 29 July 2011). ">ALEVIATE</a>; <a href="./references#CD008333-bbs2-0056" title="JPRN-UMIN000024574. Clinical trial of tocilizumab versus cyclophosphamide for microscopic polyangiitis and granulomatosis with polyangiitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000024574 (first received 1 May 2018). ">AAVTCZ</a>; <a href="./references#CD008333-bbs2-0059" title="NCT03967925. Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS. https://clinicaltrials.gov/ct2/show/NCT03967925?cond=ANCA+Associated+Vasculitis&amp;draw=2&amp;rank=12. ">COMBIVAS</a>). The <a href="./references#CD008333-bbs2-0057" title="NCT02108860. Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE). clinicaltrials.gov/ct2/show/NCT02108860 (first received 9 April 2014). ">ABROGATE</a> (NCT02108860) and <a href="./references#CD008333-bbs2-0059" title="NCT03967925. Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS. https://clinicaltrials.gov/ct2/show/NCT03967925?cond=ANCA+Associated+Vasculitis&amp;draw=2&amp;rank=12. ">COMBIVAS</a> (NCT03967925) trials are ongoing and are currently recruiting participants. <a href="./references#CD008333-bbs2-0058" title="GopaluniS , GoymerD , McClureM , CahillH , BroadhurstE , Smith, R, et al. Alemtuzumab for relapsing and refractory primary systemic vasculitis - A trial of efficacy and safety (aleviate): A randomised open-label phase ii clinical trial. In: Rheumatology. Vol. 58 Suppl 2. 2019:kez063.026. NCT01405807. Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy. clinicaltrials.gov/ct2/show/NCT01405807?id=NCT01405807&amp;rank=1 (first received 29 July 2011). ">ALEVIATE</a> trial (NCT01405807) has completed recruitment but follow‐up is ongoing. In <a href="./references#CD008333-bbs2-0056" title="JPRN-UMIN000024574. Clinical trial of tocilizumab versus cyclophosphamide for microscopic polyangiitis and granulomatosis with polyangiitis. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000024574 (first received 1 May 2018). ">AAVTCZ</a> trial (JPRN‐UMIN000024574) first enrolment was planned on 1st May 2017. </p> <p>Searching the databases reporting on AEs, we identified no relevant studies.</p> <p>Reasons for study exclusions are reported in <a href="./references#CD008333-sec-0129" title="">Characteristics of excluded studies</a>. </p> <p>We included four studies fulfilling criteria of our review (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>; <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). These studies were reported in 17 references. </p> </section> <section id="CD008333-sec-0045"> <h4 class="title">Included studies</h4> <p>The four included studies were described as RCTs. Three were described as double blind (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005.</a> One study provided no information about blinding (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). All records were available in English. We extracted data from full‐text publications for all of them, and supplemented these, when available, with data posted in clinicaltrials.gov and clinicaltrialsregister.eu (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). </p> <p>We presented details of the methods, participants, interventions and outcome measures in each study in <a href="./references#CD008333-sec-0128" title="">Characteristics of included studies</a>. </p> </section> <section id="CD008333-sec-0046"> <h4 class="title">Funding</h4> <p>One study was funded from a commercial source (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). One study was funded from a hospital research program (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). Two studies had mixed funding from public and commercial sources (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). </p> </section> <section id="CD008333-sec-0047"> <h4 class="title">Participants</h4> <p>The included studies enrolled a total of 440 participants with ANCA vasculitis. The number of participants ranged from 17 (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>) to 181 (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). All trials enrolled adult participants (18 years of older). Participants with GPA were included in three studies (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>; <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). One of those studies also included participants with MPA (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>), but the results of MPA participants were added to the GPA participant analysis. The fourth study focused on participants with relapsing or refractory EGPA (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>). Participants in <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> had refractory disease and failed previous standard treatment. </p> <p>The mean age of participants was between 48 years (control group of <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>) and 56 years (SD 14) (belimumab group of <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). The proportion of females varied between 37% in etanercept group (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>) to 62% in mepolizumab group (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>). The proportion differed more in <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> study, where there were 12.5% of females in rituximab group and 89% in infliximab group. </p> <p><b>Study duration</b> </p> <p>All studies lasted at least one year. The treatment was maintained up to12 months (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>), 52 weeks (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>), 12 months after the last participant was randomised (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>), and a median of 25 months in etanercept and 19 months in placebo group in <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> . <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> did not report on mean or median treatment duration. Reported follow‐up differed among the studies: <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> followed participants for 8 weeks, while in <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> study the average follow‐up reached 30.6 months. In <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> the mean follow‐up for the overall cohort was 27 months, and in <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> study follow‐up was approximately four years. </p> </section> <section id="CD008333-sec-0048"> <h4 class="title">Location</h4> <p>One study was carried out in the USA (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). One was conducted in several French hospitals (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). Two trials were conducted by international groups in the USA and Europe (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>). </p> </section> <section id="CD008333-sec-0049"> <h4 class="title">Setting</h4> <p>Two trials were conducted in clinical centres (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>) and one in hospitals (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). The setting for one study was not reported (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). </p> </section> <section id="CD008333-sec-0050"> <h4 class="title">Interventions</h4> <p>One study compared two pharmacological treatments: rituximab at a dose of 0.375 g/m<sup>2</sup> versus infliximab at a dose of 3 mg/kg (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). Three studies compared active drugs with placebo: belimumab at a dose of 10 mg/kg (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>), mepolizumab 300 mg (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>) and etanercept 25 mg twice a week (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). </p> </section> <section id="CD008333-sec-0051"> <h4 class="title">Major outcome measures</h4> <p>All studies reported mortality as the number of deaths (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). Remission was reported in three studies (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). One study assessed complete and partial remission, defined as the absence of active vasculitis manifestation (BVAS = 0) and partial regression of the clinical manifestations and a decrease in BVAS by &gt; 50%, respectively (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). The second study reported remission as the proportion of participants who had remission (BVAS = 0 and the receipt of prednisone at a dose of ≤ 4.0 mg/d over 52 weeks) for a certain period of time (in five categories of remission accrual; however, we described only remission for at least one week and remission for at least 24 weeks); and at weeks 36 and 48 of the study treatment period (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>). The third trial assessed disease remission defined as a BVAS/WG of 0 (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). </p> <p>Three studies also reported durable or sustained remission (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>), defined as remission for at least six months (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>); remission achieved within 24 weeks and sustained until week 52 (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>); or persistent remission, defined as remission during a long‐term follow‐up (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). In <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>, all participants were in remission at the beginning of the study. The study authors looked at the maintained remission at one and two years (BVAS = 0). </p> </section> <section id="CD008333-sec-0052"> <h4 class="title">Minor outcome measures</h4> <p>All trials published data regarding number of participants with confirmed disease relapse/flares (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> assessed time to first relapse, which was defined more broadly than vasculitis relapse, i.e. at least one major BVAS item or a minimum total BVAS score of 6 or receiving prohibited medications for any reason, which resulted in treatment failure. The study also reported sensitivity analysis using vasculitis only relapse defined as a minimum total BVAS score of 6, at least one pre‐defined major BVAS item or receiving prohibited medications for vasculitis (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). The study reported on major relapse, defined as number of participants who experienced at least 1 major BVAS item (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). Only one study assessed health‐related quality of life change, using scores for the physical and mental health aspects of the SF‐36 (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). One study reported the mean score for the VDI at the end of the trial (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). Two trials published data regarding disease damage. </p> <p>AEs were reported in all studies (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). </p> </section> <section id="CD008333-sec-0053"> <h4 class="title">Excluded studies</h4> <p>The most common reason for exclusion (n = 43) was the wrong study design. In three trials, the intervention was inappropriate. Two studies were withdrawn prior to enrolment. Reasons for exclusion are provided in <a href="./references#CD008333-sec-0129" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD008333-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>Details for each study are presented in <a href="./references#CD008333-sec-0128" title="">Characteristics of included studies</a>. <a href="#CD008333-fig-0002">Figure 2</a> shows the overall risk of bias in each domain for studies included in this review. The risk of bias by trial can be seen in <a href="#CD008333-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD008333-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008333-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008333-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008333-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>All included studies were published in full articles. None of the studies was at low risk of bias in all domains. </p> <section id="CD008333-sec-0055"> <h4 class="title">Random sequence generation</h4> <p>Randomisation methods were not reported in one study (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). In <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> the authors reported the use of an interactive web‐response system, so we assume that the sequence generation was computer‐based. In the two remaining studies, randomisation was stratified, including generating permuted blocks of varying length (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>), and centralised computer‐generated permuted‐block schedule (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>). </p> </section> <section id="CD008333-sec-0056"> <h4 class="title">Allocation</h4> <p>Allocation concealment was at unclear risk of bias in one study (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>) and at low risk of bias in the three remaining studies (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). </p> </section> <section id="CD008333-sec-0057"> <h4 class="title">Blinding</h4> <p>Three studies stated that they were double‐blind, with participants blinded (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). One study did not report detailed information about blinding we assessed the risk of bias as unclear (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). Three studies reported blinding of investigators (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). However, in one study the authors highlighted that one potential source of bias in blinding personnel was injection site reactions in the treatment group (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). Blinding of outcome assessors was reported in three studies and those trials were judged to be at low risk of bias (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). In one study, blinding of outcome assessors was not reported and we assessed the risk of bias as unclear (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). </p> </section> <section id="CD008333-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>We judged all four studies contributing data to be at a low risk of attrition bias (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). </p> </section> <section id="CD008333-sec-0059"> <h4 class="title">Selective reporting</h4> <p>For one study, no protocol was available, so it was not possible to judge if all outcomes were reported. However, the study reported all important vasculitis outcomes and AEs (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). In another study, all of its protocol‐specified major and minor outcomes were reported, but other benefit endpoints listed in the protocol were not reported (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). We judged two studies with protocols to be at high risk of bias, as data on treatment outcomes were reported incompletely (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). </p> </section> <section id="CD008333-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>Three studies appeared free of other potential sources of bias (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). </p> </section> </section> <section id="CD008333-sec-0061"> <h3 class="title" id="CD008333-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD008333-tbl-0001"><b>Summary of findings 1</b> Mepolizumab compared to placebo for adults with EGPA ANCA‐associated vasculitis</a>; <a href="./full#CD008333-tbl-0002"><b>Summary of findings 2</b> Active drug (etanercept or belimumab) with standard therapy compared to standard therapy with placebo for adults with GPA ANCA‐associated vasculitis</a>; <a href="./full#CD008333-tbl-0003"><b>Summary of findings 3</b> Infliximab compared to rituximab for adults with refractory GPA ANCA‐associated vasculitis</a> </p> <p>The studies included in the review enrolled participants with GPA (three studies: <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>) or EGPA (one study: <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>) or MPA (one study: <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). Studies compared a single drug with placebo or with another active drug. The population in <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> was mixed and included mostly participants with GPA (79%), but also with MPA (21%). Therefore, we summarised the results from all studies for the GPA and EGPA populations separately, as well as for comparisons of active drug with placebo and active drug with another active drug. </p> <section id="CD008333-sec-0062"> <h4 class="title"><i>Comparison 1: Mepolizumab compared to placebo in adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis</i> </h4> <section id="CD008333-sec-0063"> <h5 class="title">Major outcomes</h5> <section id="CD008333-sec-0064"> <h6 class="title">Mortality</h6> <p>In <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>, one death was reported in mepolizumab group and no deaths in placebo group (Peto OR 7.39, 95% CI 0.15 to 372.38; <a href="./references#CD008333-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD008333-sec-0065"> <h6 class="title">Remission</h6> <p><a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> reported this outcome as accrued weeks of remission over a 52‐week period. Overall, more participants had any remission (for at least one week) in the mepolizumab group compared with the placebo group (RR 2.77, 95% CI 1.62 to 4.74; Relative benefit increase 177%, 95% CI 62 to 374%; RD 33.8%, 95% CI 11.9% to 71.5%; NNTB 3, 95% Cl 2 to 6; <a href="./references#CD008333-fig-0005" title="">Analysis 1.2</a>) and more participants had at least 24 weeks of accrued remission (28% versus 3%; RR 9.5, 95% CI 2.3 to 39.2; Relative benefit increase 850%, 95% CI 130 to 3820%; RD 25%, 95% Cl 3.8% to 112%; NNTB 4, 95% Cl 3 to 8; <a href="./references#CD008333-fig-0005" title="">Analysis 1.2</a>). </p> <p>In the analysis of accrued weeks of remission over follow‐up, more participants in the mepolizumab group (28%) had ≥ 24 weeks of accrued remission over 52 weeks of follow‐up than in the placebo group (3%) (OR 5.91, 95% CI 2.68 to 13.0). </p> </section> <section id="CD008333-sec-0066"> <h6 class="title">Durable remission</h6> <p>In <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>, durable remission was defined as remission within the first 24 weeks that was sustained until week 52. More participants in the mepolizumab group, compared with control group, experienced durable remission (13 versus 1 participants; RR 13.0, 95% CI 1.75 to 96.33; Relative benefit increase 1200%, 95% CI 75 to 9563%; RD 17.6%, 95% CI 1.1 to 140.2%; NNTB 6, 95% Cl 4 to 13); <a href="./references#CD008333-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD008333-sec-0067"> <h6 class="title">Disease relapse</h6> <p><a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> reported time to first relapse over 52 weeks of the study, and the number of participants with first EGPA relapse. Fewer participants relapsed in the mepolizumab group than in the placebo group (56% versus 82%; RR 0.68, 95% CI 0.53 to 0.86; RRR 32%, 95% CI 14 to 47%; RD ‐26.4%, 95% CI from ‐38.7 to ‐11.5; NNTB 4, 95% CI 3 to 9; <a href="./references#CD008333-fig-0007" title="">Analysis 1.4</a>). The time to relapse was longer in active treatment, compared with the placebo group (hazard ratio (HR) 0.32, 95% CI 0.21 to 0.5). The study reported details regarding relapses in the mepolizumab and placebo groups in the following categories: any vasculitis relapses (43% versus 65% of participants); any asthma (37% versus 60%); any sinonasal relapses (35% versus 51%); vasculitis only (18% versus 22%); asthma only (19% versus 32%); sinonasal only (6% versus 12%); and any combinations of these. </p> </section> <section id="CD008333-sec-0068"> <h6 class="title">Total AEs</h6> <p><a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> reported similar rates of participants with any AEs in the mepolizumab and placebo groups (97% versus 94%; RR 1.03, 95% CI 0.96 to 1.11; RD 3%, 95% CI from ‐4 to 1; <a href="./references#CD008333-fig-0008" title="">Analysis 1.5</a>), and also reported any event considered by the investigator to be related to the trial agent (51% versus 35%; RR 1.46, 95% CI 0.98 to 2.17; RD 16%, 95% CI from ‐0.3 to 33; <a href="./references#CD008333-fig-0008" title="">Analysis 1.5</a>). The most common AEs reported in the study were headache (32% versus 18%), nasopharyngitis (18% versus 24%), arthralgia (22% versus 18%), sinusitis (21% versus 16%), and upper respiratory tract infection (21% versus 16%). The number of participants who experienced local injection‐site reactions and systemic reaction was similar in the two groups (15% versus 13% and 6% versus 1% respectively). For serious AEs, see <a href="./references#CD008333-fig-0009" title="">Analysis 1.6</a>. </p> </section> <section id="CD008333-sec-0069"> <h6 class="title">Serious and severe AEs</h6> <p><a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> defined all serious AEs as "any untoward medical occurrence that resulted in death, was life‐threatening, resulted in hospitalisation or prolongation of existing hospitalisation, resulted in disability or incapacity, was a congenital anomaly or birth defect, or was indicative of possible drug‐induced liver injury with hyperbilirubinaemia" and specific serious events defined as serious AE which was considered by the investigator as related to the trial agent. The most common serious AE was exacerbation or worsening of asthma (3% of the participants in the mepolizumab group versus 6% of participants in the placebo group).The percentages of participants with any serious AEs or any serious AEs considered to be related to the trial agents were similar in the mepolizumab and placebo groups (18% versus 26%, RR 0.67, 95% CI 0.35 to 1.28; RD ‐8.7, 95% CI from ‐17.2 to 7.4; and 4% versus 4%; RR 1.0, 95% CI 0.21 to 4.78; RD 0, 95% CI from ‐3.5% to 16.7%; <a href="./references#CD008333-fig-0009" title="">Analysis 1.6</a>). One participant in the mepolizumab group died from cardiac arrest during the trial, this participant had a history of coronary artery disease. </p> </section> <section id="CD008333-sec-0070"> <h6 class="title">Withdrawals due to AEs</h6> <p><a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> reported similar number of participants withdrawn from the mepolizumab and placebo groups due to AEs (3% versus 1%; RR 2.0, 95% CI 0.19 to 21.54; RD 1.5% 95% Cl ‐1.2% to 30.2%; <a href="./references#CD008333-fig-0010" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD008333-sec-0071"> <h5 class="title">Minor outcomes</h5> <section id="CD008333-sec-0072"> <h6 class="title">Treatment response</h6> <p><a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> did not analyse treatment response as an outcome. </p> </section> <section id="CD008333-sec-0073"> <h6 class="title">Health‐related quality of life</h6> <p><a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> provided no results of quality of life assessments. </p> </section> <section id="CD008333-sec-0074"> <h6 class="title">Control of asthma/sinonasal disease</h6> <p><a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> reported changes from baseline in ACQ‐6 and SNOT‐22 scores, but only on graphs. We contacted the study authors to obtain numeric data, without success. To estimate the effect, we used software to read the values from the graph. Values were presented as mean change from baseline in both groups (<a href="./references#CD008333-fig-0011" title="">Analysis 1.8</a>; <a href="./references#CD008333-fig-0012" title="">Analysis 1.9</a>). For ACQ‐6, the change from baseline was similar in both groups; the estimated difference was ‐0.3 (95% CI ‐0.6 to 0.00) (<a href="./references#CD008333-fig-0011" title="">Analysis 1.8</a>). The minimal clinically important difference, as reported by the authors, is 0.5. </p> <p>For SNOT‐22, the change from baseline was similar in both groups; the estimated difference was ‐4.66 (95% CI ‐10.69 to 1.36) (<a href="./references#CD008333-fig-0012" title="">Analysis 1.9</a>). The minimal clinically important difference, as reported by the authors, is 8.9. </p> </section> <section id="CD008333-sec-0075"> <h6 class="title">Disease damage</h6> <p><a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> reported data on change from baseline in the VDI in the form of a graph. We contacted the study authors to obtain numeric data, without success. To estimate the effect, we used software to read the values from the graph. Values were presented as mean change from baseline in both groups (<a href="./references#CD008333-fig-0013" title="">Analysis 1.10</a>). The change from baseline was similar in both groups; the estimated difference was ‐0.07 (95% CI ‐0.37 to 0.23) (<a href="./references#CD008333-fig-0011" title="">Analysis 1.8</a>). The minimal clinically important difference has not been determined. </p> </section> </section> </section> <section id="CD008333-sec-0076"> <h4 class="title">Comparison 2: Etanercept or belimumab compared with placebo in adults with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis </h4> <section id="CD008333-sec-0077"> <h5 class="title">Major outcomes</h5> <section id="CD008333-sec-0078"> <h6 class="title">Mortality</h6> <p>In <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>, four deaths were observed in the group receiving etanercept and two deaths in the group receiving placebo. In <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>, one death was observed in the belimumab group and no deaths were observed in the placebo group. When we pooled the results of two studies comparing active drug with placebo, we found similar odds of death in both groups (Peto OR 2.45, 95% CI 0.55 to 10.97; <a href="./references#CD008333-fig-0014" title="">Analysis 2.1</a>). </p> </section> <section id="CD008333-sec-0079"> <h6 class="title">Remission</h6> <p><a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> reported remission, defined as a BVAS/WG of 0 at any time during the trial (as a minor outcome), in 80 participants in the etanercept group and 84 participants in the placebo group (RR 0.07, 95% CI 0.89 to 1.07; <a href="./references#CD008333-fig-0015" title="">Analysis 2.2</a>). <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> stratified participants at randomisation according to the disease severity at baseline (severe or limited) and found similar effect in both groups (HR 0.91, 95% CI 0.63 to 1.32 and HR 0.8, 95% CI 0.44 to 1.43, P for interaction = 0.77). </p> </section> <section id="CD008333-sec-0080"> <h6 class="title">Durable remission</h6> <p>In <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>, sustained remission was defined as BVAS/WG = 0 for ≥ 6 months. The number of participants with sustained remission in the etanercept and placebo groups was similar (62 versus 64 participants; RR 0.93, 95% CI 0.77 to 1.11; RD ‐5.3%, 95% Cl ‐17.3% to 8.3%; <a href="./references#CD008333-fig-0016" title="">Analysis 2.3</a>). The study stratified participants at randomisation according to the disease severity at baseline (severe or limited) and found similar effects in both groups (HR 0.91, 95% CI 0.6 to 1.37; and HR 0.82, 95% CI 0.42 to 1.6; P for interaction = 0.85). </p> <p>At baseline, all participants in <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> were in remission. In our analysis, we used the total number of participants included in an intention‐to‐treat (ITT) analysis. <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> reported that, at the year one, week 48 time point, 38 (71.7% of all included in ITT) participants were in remission in the belimumab group and 43 (82.69% of all included in ITT) were in remission in the placebo group (RR 0.87, 95% CI 0.7 to 1.07; calculated using RevMan calculator). At the year two, week 28 time point, 21 (39.62% of all included in ITT) participants were in remission in the belimumab group and 26 (50% of all included in ITT) were in remission in the placebo group (RR 0.79, 95% CI 0.52 to 1.22; calculated using RevMan calculator) . </p> </section> <section id="CD008333-sec-0081"> <h6 class="title">Disease flare/relapse</h6> <p><a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> reported that similar percentage of participants in etanercept and placebo groups had no disease flares during the study (42.7% versus 42.9%; RR 0.98, 95% CI 0.76 to 1.27; RD ‐1.1%, 95% Cl ‐13.7% to 15.4%; <a href="./references#CD008333-fig-0018" title="">Analysis 2.5</a>) and the number of any disease flares per 100 person‐years was similar between the groups (66.3 versus 74.1 per 100 person‐years, HR 0.89, 95% CI 0.62 to 1.28) as was the number of severe flares (14.9 versus 12.8 per 100 person‐years, HR 1.05, 95% CI 0.61 to 1.8). Similar percentages of participants who achieved sustained remission relapsed in both groups (30.6% of 62 participants in etanercept versus 32.8% of 64 participants in placebo group). </p> <p><a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> reported a similar percentage of participants in the belimumab and placebo groups who experienced vasculitis relapse as the first relapse (11.3% versus 15.4%; RR 0.74, 95% CI 0.27 to 1.97; RD ‐4%, 95% CI from ‐17 to 9; <a href="./references#CD008333-fig-0017" title="">Analysis 2.4</a>) and among participants with relapse the time to first vasculitis relapse was similar in the belimumab and placebo group (median 251 (range 25‐371) days, 105.5 (range 15‐789) days; HR 0.88, 95% CI 0.29 to 2.65). In <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>, the first protocol‐specified event that included relapse was defined as a BVAS score of ≥ 6, presence of at least one predefined major BVAS item, or the receipt of prohibited medications for any reason. One participant in the belimumab group had a major relapse during the double‐blind phase of the study. In the placebo group, none of participants experienced major relapse (RR 2.94, 95% CI 0.12 to 70.67; RD 2%, 95% CI from ‐3 to 7; <a href="./references#CD008333-fig-0017" title="">Analysis 2.4</a>). </p> </section> <section id="CD008333-sec-0082"> <h6 class="title">Total AEs</h6> <p><a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> reported AEs defined as any medical condition in participants who received etanercept and were graded according to the National Cancer Institute Toxicity Grading Scale. The study reported three types of AEs: severe (grade 3), life‐threatening (grade 4) and deaths as fatal AEs (grade 5). For serious or severe AEs, see <a href="./references#CD008333-fig-0021" title="">Analysis 2.8</a>). </p> <p><a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> reported specific types of AEs such as cytopenias, infections, congestive heart failure and venous thrombotic events. The frequency of cytopenias, infections, venous trombotic events and congestive heart failure was similar in etanercept and placebo group. Similar numbers of participants experienced grade 2 to grade 5 infections (49.4% in each group) and venous thrombotic events (10 events in each group; P = 0.92). </p> <p><a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> defined AEs as an untoward medical occurrence in a participant, temporally associated with the use of a drug, whether or not it was considered to be related to the medicinal product. In this study, 92.5% participants in belimumab group experienced at least one adverse event, compared to 82.7% participants in the placebo group, at any time during the study (see <a href="./references#CD008333-fig-0019" title="">Analysis 2.6</a>). Most AEs were infections and infestations (56.6% of participants in the belimumab group and 57.7% of participants in the placebo group). The study reported similar percentages of participants in both the belimumab and placebo groups with AEs other than serious (60.38% versus 63.46%; RR 0.95, 95% CI 0.7 to 1.28; RD ‐3.2%, 95% CI from ‐19 to 17.8; <a href="./references#CD008333-fig-0020" title="">Analysis 2.7</a>). </p> </section> <section id="CD008333-sec-0083"> <h6 class="title">Serious and severe AEs</h6> <p><a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> provided the definition of severe AEs as adverse event grade 3, life‐threatening events as adverse event grade 4 and fatal AEs as grade 5. The study reported similar percentages of participants with such events in the etanercept and placebo groups (56.2% versus 57.1%), which included deaths (four versus two cases). <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> did not report serious AEs. </p> <p><a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> defined serious AEs as AEs that resulted in death, were life‐threatening, required hospitalisation or prolongation of hospitalizations, or resulted in disability or incapacity. There was one death in the belimumab group and no deaths in the placebo group (see <a href="./references#CD008333-fig-0014" title="">Analysis 2.1</a>). The study reported similar percentage of participants with serious AEs in the belimumab and placebo groups (33.96% versus 30.77%). The study reported that there were four cases of any malignancies (including non‐melanoma skin cancer) in the belimumab group (anal cancer, basal cell carcinoma, plasma cell myeloma and one malignancy not specified) with no such events in control group. There was also one case of ischaemic stroke (resulting in death). One participant in the control group was diagnosed with anaemia, one with pancytopenia, and one with sinus bradycardia. One participant in the belimumab group experienced acute kidney injury. Severe AEs were reported in 11 (20.8%) participants in the belimumab group and seven (13.5%) participants in the placebo group. When we pooled the results of both studies (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>) we found non significant difference between the groups in frequency of serious or severe AEs (RR 1.0, 95% CI 0.8 to 1.27; RD 0, 95% CI from ‐9.5% to 12.8%; <a href="./references#CD008333-fig-0021" title="">Analysis 2.8</a>). </p> <p><a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> reported six solid cancers (two cases of mucinous adenocarcinoma of the colon, one metastatic cholangiocarcinoma, one renal‐cell carcinoma, one breast carcinoma, and one liposarcoma), all in the etanercept group (RR 13.29, 95% CI 0.76 to 232.45; RD 0, 95% CI 0 to 0; <a href="./references#CD008333-fig-0022" title="">Analysis 2.9</a>). The rate of cancers in the etanercept and placebo groups were similar (three cases versus four cases of cutaneous basal‐cell or squamous‐cell carcinomas). It is also important to mention AEs during long‐term post‐trial follow‐up. These data were available for 153 participants (85% of the original cohort), with a median follow‐up time of 43 months. During the follow‐up, the rates of cancer were similar in the etanercept and placebo groups (10% versus 7%; RR 1.58, 95% 0.54 to 4.61; RD 3.8%, 95% CI from ‐3% to 23.4%; <a href="./references#CD008333-fig-0022" title="">Analysis 2.9</a>). However, the combined risk of solid malignancy from time of trial enrolment remained higher for the etanercept group (relative risk increase (RRI) 186%, 95% CI 8 to 662; RD 10%, 95% CI 1% to 19%) (<a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). </p> </section> <section id="CD008333-sec-0084"> <h6 class="title">Withdrawals due to AEs</h6> <p><a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> reported nine withdrawals due to AEs in etanercept group and three withdrawals in placebo group. In the <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> publications we identified some discrepancies in the numbers of participants withdrawn from the study. In a figure depicting participant flow, the authors reported seven withdrawals due to AEs in the belimumab group and three withdrawals in placebo group. However, in the results section describing AEs, the authors reported that eight participants in the belimumab group and six participants in the placebo group had AEs leading to study withdrawal. We contacted the authors to clarify this and we received information that the discrepancies were due to different categorisation of AEs in those two study sites, specifically vasculitis flares (classified as lack of efficacy on in the patient flow figure and as AE in the AEs section). The study authors suggested that we use of the number of withdrawals due to AEs presented on the figure depicting patient flow. When we pooled the results from both studies, we observed an increased risk of withdrawal due to AEs in the active drug group as compared with the placebo group (RR 2.66, 95% CI 1.07 to 6.59; RRI 166%, 95% CI 7 to 559%; RD 7%, 95% CI 0.3% to 23.5%; NNTH 15, 95% CI 8 to 100; <a href="./references#CD008333-fig-0023" title="">Analysis 2.10</a>). We used the number of participants withdrawn reported in AEs section of BREVAS study in sensitivity analysis, where the difference became non‐significant (<a href="./references#CD008333-fig-0032" title="">Analysis 4.1</a>). </p> </section> </section> <section id="CD008333-sec-0085"> <h5 class="title">Minor outcomes</h5> <section id="CD008333-sec-0086"> <h6 class="title">Treatment response</h6> <p>Treatment response was reported in <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> study as sustained low level of disease activity (BVAS/WG &lt; 3 for at least 6 months) and no significant difference was found between the etanercept and control groups (RR 0.96, 95% CI 0.86 to 1.06; RD ‐4% 95%Cl ‐13% to 5%; <a href="./references#CD008333-fig-0024" title="">Analysis 2.11</a>). The study stratified participants at randomisation according to the disease severity at baseline (severe or limited) and found a similar effect in both groups (HR 0.7, 95%CI 0.48 to 1.03 and 1.24, 95% CI 0.69 to 2.24, P for interaction = 0.11). </p> </section> <section id="CD008333-sec-0087"> <h6 class="title">Health‐related quality of life</h6> <p>In <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>, the assessment of health‐related quality of life was based on the SF‐36 questionnaire. The results were only reported as improvements in physical and mental health domains in the etanercept and placebo groups (7.7 and 5.7 versus 8.4 and 8.0). </p> </section> <section id="CD008333-sec-0088"> <h6 class="title">Control of asthma/sinonasal disease</h6> <p><a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> and <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> did not report on on this outcome. </p> </section> <section id="CD008333-sec-0089"> <h6 class="title">Disease damage</h6> <p><a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> reported a mean score of VDI at baseline and at the end of the trial. The increase in the score was similar in the etanercept and control groups (from 1.6 to 2.0 versus from 1.0 to 1.7, P = 0.5). In all participants the most frequently reported items were hearing loss (25.6%) and proteinuria (&gt; 0.5 g of protein in 24 hours; 18.9%). </p> <p><a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> reported minimal changes in VDI score in the belimumab group (year one, week 48: 0.1 ± 0.38; year two, week 24: 0.2 ± 0.50) and no change in the placebo group (year one, week 48: 0.0 ± 0.15; year two, week 24: 0.0 ± 0.00). </p> </section> </section> </section> <section id="CD008333-sec-0090"> <h4 class="title">Comparison 3: Infliximab versus rituximab added to steroids and cytotoxic agents in adults with refractory GPA </h4> <section id="CD008333-sec-0091"> <h5 class="title">Major outcomes</h5> <section id="CD008333-sec-0092"> <h6 class="title">Mortality</h6> <p>In a single study comparing two active drugs, one participant died in each group (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>) during 12 months of the study (Peto OR 0.88, 95% CI 0.05 to 15.51; <a href="./references#CD008333-fig-0014" title="">Analysis 2.1</a>). In additional follow‐up (mean 30.6 months SD 15.4), two more deaths were reported, one in the infliximab group and one in the rituximab group. </p> </section> <section id="CD008333-sec-0093"> <h6 class="title">Remission</h6> <p>A single study by <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> reported complete remission (CR), defined as BVAS = 0. During 12 months of the study, two participants in the infliximab group had complete remission, while in the rituximab group four participants had complete remission. No beneficial effect in complete remission was found in the case of infliximab in comparison with rituximab (RR 0.44, 95% CI 0.11 to 1.81; RD ‐28%, 95% Cl ‐44.5% to 40.5%; <a href="./references#CD008333-fig-0015" title="">Analysis 2.2</a>). During follow‐up, in the infliximab group, one participant remained in remission. Two participants relapsed, were switched to other treatments and achieved remission. In the rituximab group, three participants remained in remission in the long term. One participant relapsed, achieved remission again and remained in remission. </p> </section> <section id="CD008333-sec-0094"> <h6 class="title">Durable remission</h6> <p><a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> reported long‐term complete remissions, defined as persistent remission during additional follow‐up beyond 12 months. The study reported one long‐term remission in the infliximab group during 28.9 +/‐ 15.4 months and four long‐term complete remissions during 32.9 +/‐ 16.7 months of follow‐up in rituximab group (RR 0.22, 95% CI 0.03 to 1.60; RD ‐39%, 95% Cl ‐48.5% to 30%; <a href="./references#CD008333-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD008333-sec-0095"> <h6 class="title">Disease flare/relapse</h6> <p><a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> reported that during long‐term follow‐up, two out of three participants in remission relapsed, while in rituximab one out of five participants in remission relapsed but achieved complete response again. </p> </section> <section id="CD008333-sec-0096"> <h6 class="title">Total AEs</h6> <p><a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> reported AEs graded according to the World Health Organization classification (2003), defined AEs as severe, moderate and mild events. Two participants in the infliximab group experienced incidental or mild allergic reactions during infusion. These were one facial erythema and one transient bronchospasm that was described as severe and resulted in withdrawal from the trial. Two participants (one in the infliximab group, one in the rituximab group) experienced severe AEs and died. During the additional long‐term follow‐up in the infliximab group, with mean time of follow‐up 30.6 ± 15.4 months and with all participants available, one participant had infliximab‐related skin rash; one participant experienced hepatitis subsequent to cytomegalovirus infection nine months after the end of the treatment protocol. In the rituximab group, one participant was diagnosed with prostate carcinoma 27 months after the last rituximab infusion. One participant was diagnosed with pancreatic carcinoma two months after the last rituximab infusion, and died three months later. </p> </section> <section id="CD008333-sec-0097"> <h6 class="title">Serious and severe AEs</h6> <p><a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> reported severe AEs and deaths. There was one severe allergic reaction (transient bronchospasm) in one participant in the infliximab group, and there were two deaths during the study (one in each group) (RR 1.78, 95% CI 0.2 to 16.1; RD 9.8%, 95% Cl ‐10% to 188.8%; <a href="./references#CD008333-fig-0021" title="">Analysis 2.8</a>). Two additional deaths occurred during follow‐up (one in each group). One participant in infliximab group died of invasive aspergillosis at month 2, 60 days after first infusion (severe AE). One participant in the rituximab group experienced sudden death on day 23 of the trial, with no autopsy and no obvious explanation. </p> </section> <section id="CD008333-sec-0098"> <h6 class="title">Withdrawals due to AEs</h6> <p><a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> reported one withdrawal due to AEs in the infliximab group and did not report withdrawals in the rituximab group (RR 2.7, 95% CI 0.13 to 58.24; RD 0 95% Cl 0% to 0%; <a href="./references#CD008333-fig-0023" title="">Analysis 2.10</a>). </p> </section> </section> <section id="CD008333-sec-0099"> <h5 class="title">Minor outcomes</h5> <section id="CD008333-sec-0100"> <h6 class="title">Treatment response</h6> <p><a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> reported partial remission (PR), defined as partial regression of the disease and &lt; 50% BVAS (as a part of major outcome). During 12 months of the study, one participant in the infliximab group and one participant in the rituximab group had PR (RR 0.89, 95 CI 0.07 to 12.0; RD ‐1.4% 95%Cl ‐11.6% to 137.5%; <a href="./references#CD008333-fig-0024" title="">Analysis 2.11</a>). </p> </section> <section id="CD008333-sec-0101"> <h6 class="title">Health‐related quality of life</h6> <p><a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> did not report on quality of life. </p> </section> <section id="CD008333-sec-0102"> <h6 class="title">Control of asthma/sinonasal disease</h6> <p><a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> did not report on this outcome. </p> </section> <section id="CD008333-sec-0103"> <h6 class="title">Disease damage</h6> <p><a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a> did not report on this outcome. </p> </section> </section> </section> <section id="CD008333-sec-0104"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses for <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a> in Comparison 2, including all randomised and control group participants, assumed to have the best possible outcome. Sensitivity analyses did not change the results of the trial reported for the main analyses (<a href="./references#CD008333-fig-0025" title="">Analysis 3.1</a>; <a href="./references#CD008333-fig-0026" title="">Analysis 3.2</a>; <a href="./references#CD008333-fig-0027" title="">Analysis 3.3</a>; <a href="./references#CD008333-fig-0028" title="">Analysis 3.4</a>; <a href="./references#CD008333-fig-0029" title="">Analysis 3.5</a>; <a href="./references#CD008333-fig-0030" title="">Analysis 3.6</a>; <a href="./references#CD008333-fig-0031" title="">Analysis 3.7</a>). </p> <p>Our primary plan outlined in the protocol was to perform analyses across all types of ANCA‐associated vasculitis, but based on clinical heterogeneity as outlined above, we decided to pool the data separately for each type of AAV. We performed sensitivity analysis by pooling the different AAV types together for the outcomes for which we had data from more than one study (<a href="./references#CD008333-fig-0033" title="">Analysis 5.1</a>; <a href="./references#CD008333-fig-0034" title="">Analysis 5.2</a>; <a href="./references#CD008333-fig-0035" title="">Analysis 5.3</a>; <a href="./references#CD008333-fig-0036" title="">Analysis 5.4</a>; <a href="./references#CD008333-fig-0037" title="">Analysis 5.5</a>; <a href="./references#CD008333-fig-0038" title="">Analysis 5.6</a>). The results were similar across AAV‐type and treatment comparisons subgroups for mortality, disease relapse, any serious or severe AEs and withdrawals due to AEs (<a href="./references#CD008333-fig-0033" title="">Analysis 5.1</a>; <a href="./references#CD008333-fig-0036" title="">Analysis 5.4</a>; <a href="./references#CD008333-fig-0037" title="">Analysis 5.5</a>; <a href="./references#CD008333-fig-0038" title="">Analysis 5.6</a>, but the effects differed across AAV‐type and treatment comparisons for any remission and durable remission (<a href="./references#CD008333-fig-0034" title="">Analysis 5.2</a>; <a href="./references#CD008333-fig-0035" title="">Analysis 5.3</a>). This analysis is limited by the low number of studies (single studies in most subgroups). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008333-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008333-sec-0105"></div> <section id="CD008333-sec-0106"> <h3 class="title" id="CD008333-sec-0106">Summary of main results</h3> <p>The aim of this review was to provide an overview of the benefits and harms of anti‐cytokine targeted therapies in patients with ANCA‐associated vasculitis. The review identified four RCTs investigating the effects of anti‐cytokine interventions on mortality, remission, durable remission, disease flare, any AEs, any serious AEs, and any withdrawals due to AEs. Due to differences in studied populations and treatments, the results were not pooled together, but were analysed in three comparisons: 1) mepolizumab versus placebo in relapsing or refractory EGPA; 2) etanercept/belimumab added to standard therapy versus standard therapy with placebo in GPA (with 8% participants with MPA); and 3) infliximab versus rituximab in refractory GPA. </p> <p>A single trial of mepolizumab compared with placebo in relapsing or refractory EGPA showed that the use of experimental treatment probably decreases the risk of disease relapse (moderate‐certainty evidence) and may increase the probability of accruing at least 24 weeks of remission and durable remission (low‐certainty evidence). However, due to low‐certainty evidence and a low number of events there is uncertainty regarding the effect of mepolizumab on mortality. The evidence on any AEs, any severe adverse effects and any withdrawals due to adverse effects was limited, as the study included a low number of participants. </p> <p>We found low‐certainty evidence that in patients with GPA (with 8% participants with MPA), etanercept or belimumab added to standard therapy as compared with standard therapy alone may increase the probability of withdrawal due to AE; etanercept or belimumab may have little or no impact on serious AEs; etanercept may have little or no impact on durable remission, and belimumab may have little or no impact on major relapse. Moderate‐certainty evidence suggests little or no improvement in disease flare with the use of etanercept. Low‐certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy, when compared with standard therapy, does not increase or reduce mortality. </p> <p>Due to very low‐certainty evidence for all outcomes, the effects of infliximab as compared to rituximab in the management of patients with refractory GPA is uncertain. </p> <p>Overall, based on obtained data, there is low‐ to moderate‐certainty evidence of the clinically relevant effect of one specific anti‐cytokine, mepolizumab, in one form of ANCA‐associated vasculitis (relapsing or refractory EGPA), with uncertain side effect risk; but none for any other anti‐cytokines in any vasculitis. </p> </section> <section id="CD008333-sec-0107"> <h3 class="title" id="CD008333-sec-0107">Overall completeness and applicability of evidence</h3> <p>It should be highlighted that only four studies were included in the review, of which three had major limitations and one was conducted in a small number of participants. This is a significant limitation of the available data. Three additional studies were planned, but were withdrawn prior to enrolment or closed without being completed, and do not add evidence to our systematic review. We have also identified four ongoing studies that may add evidence in future updates of the review. </p> <p>The majority of included studies (three of the four included) were conducted mainly in participants with GPA. However, one of these studies included a small group of participants with refractory disease, so it had to be analysed separately and its results may not be applicable to patients with non‐refractory disease. The remaining two studies included mainly participants with GPA, but also a small subgroup of participants with MPA, who comprised 8% of the overall pooled population from those two studies. Therefore, the results of these three studies, mainly in participants with GPA, may not be applicable to patients with MPA or other form of ANCA‐associated vasculitis, such as EGPA. </p> <p>One study was conducted in participants with EGPA. The authors reported that compared to placebo in relapsing or refractory EGPA participants, mepolizumab resulted in higher rates of remission (including durable remission) and fewer disease relapse events. The results of this study may not be applicable to patients with other forms of ANCA‐associated vasculitis, such as GPA and MPA. </p> <p>The studies included in the review assessed all or most of the major outcomes defined by this review, but they included small numbers of patients and for several outcomes the confidence intervals were wide and imprecise. <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> showed the beneficial effect of mepolizumab in relapsing or refractory EGPA, which maybe considered clinically relevant. However, the risk of side effects is uncertain, as the number of patients in the study was not large enough to assess safety. </p> <p>None of the studies included in this systematic review address potential benefit in lowering the mortality in ANCA‐associated vasculitis, as the number of death events was too low to draw any conclusions. </p> <p>To summarise, the studies identified by this review addressed questions for single drugs in single groups of patients. There are still many gaps in evidence, suggesting the need for further studies. The effects of interventions in patients with other forms of ANCA‐associated vasculitis are not sufficiently covered by current evidence. Further investigation of safety of these interventions is also needed. </p> </section> <section id="CD008333-sec-0108"> <h3 class="title" id="CD008333-sec-0108">Quality of the evidence</h3> <p>All the included studies were described as double‐blind, randomised placebo‐controlled trials. Two studies were judged to be at low risk of bias in all domains except selective reporting, which was judged to be at high risk of bias (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). One study was judged to be at unclear risk of bias for random sequence generation, high risk of bias for blinding, unclear risk of bias for allocation and low risk of bias for incomplete outcome data (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). Additionally for this study, we had concern about risk of bias in selective outcome reporting, as there was no protocol available (<a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>). One study did not provide information about all outcomes specified in the protocol (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>). Three studies appeared free of other potential sources of bias. The studies enrolled different types of patients. Patients with GPA were included in three studies (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a>; <a href="./references#CD008333-bbs2-0002" title="deMenthonM , CohenP , PagnouxC , BuchlerM , SibiliaJ , DétréeF , et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clinical and Experimental Rheumatology2011;29(1 suppl 64):S63-71. ">de Menthon 2011</a>; <a href="./references#CD008333-bbs2-0004" title="Performance of the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) in a randomized clinical trial. Cleveland Clinic Journal of Medicine2002;69:SII-SSI. SeoP , MinYI , HolbrookJT , HoffmanGS , MerkelPA , SpieraR , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism2005;52(7):2168-78. SilvaF , SeoP , SchroederDR , StoneJH , MerkelPA , HoffmanGS , et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s) long-term follow-up of a multicenter longitudinal cohort. Arthritis &amp; Rheumatology2011;63(8):2495-503. StoneJH , HolbrookJT , MarriottMA , TibbsAK , SejismundoLP , MinYI , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism2006;54(5):1608-18. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials2002;23(4):450-68. Wegener's Granulomatosis Etanercept Trial Research, Group. Etanercept plus standard therapy for Wegener's granulomatosis. The New England Journal of Medicine2005;352(4):351-61. ">WGET 2005</a>). However, <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> included a mixed population, with the majority of participants with GPA and one fifth of the participants with MPA, analysed together. Another study enrolled participants with relapsing or refractory EGPA (<a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a>). For this reason, we analysed these separately. However, all of the analyses provided imprecise results with wide CIs. Publication bias was not assessed due to the low number of studies. For the comparison of mepolizumab and placebo in patients with EGPA, we judged the certainty of the evidence for the following outcomes to be low: mortality, remission accrued for at least 24 weeks, durable remission, any AE, any serious AEs and any withdrawals due to AEs. We judged the cetertainty of evidence to be moderate for disease relapse. The certainty of evidence was downgraded due to imprecision. For the comparison of etanercept/belimumab and placebo in patients with GPA/MPA, we judged the certainty of evidence to be low for mortality, remission, durable remission, major relapse, any severe or serious AEs, and any withdrawals due to AEs. We judged the certainty of evidence to be moderate for disease flare. The certainty of evidence was downgraded due to risk of bias (high risk of selective outcome reporting in both studies) and/or for imprecision. For the comparison of infliximab with rituximab, the certainty of evidence was very low for all outcomes. It was downgraded for risk of bias in the study and imprecision. </p> </section> <section id="CD008333-sec-0109"> <h3 class="title" id="CD008333-sec-0109">Potential biases in the review process</h3> <p>We conducted an extensive search to identify relevant studies. In addition to a comprehensive database search we sought information from other sources, such as registries of clinical trials, the websites of regulatory agencies, pharmacovigilance agencies and drug safety updates. We checked for additional data in all primary studies, review articles and relevant manufacturer websites. We searched PubMed for errata or retractions from included studies published in full‐text. Study selection on the basis of titles and abstracts and on the basis of full texts, data extraction and risk of bias assessments were done by two review authors independently and additionally checked by a senior review author to reduce chance of errors, while our GRADE assessment was done by a junior review author and checked by two senior review authors. </p> </section> <section id="CD008333-sec-0110"> <h3 class="title" id="CD008333-sec-0110">Agreements and disagreements with other studies or reviews</h3> <p>This Cochrane Review stays in agreement with other literature reviews in this topic (<a href="./references#CD008333-bbs2-0046" title="Silva-FernandezL , LozaE , Martinez-TaboadaVM , BlancoR , Rua-FigueroaI , Pego-ReigosaJM , et al. Biological therapy for systemic vasculitis: a systematic review. Seminars in Arthritis and Rheumatism2014;43(4):542-57. ">Silva‐Fernandez 2014</a>, <a href="./references#CD008333-bbs2-0024" title="LutaloMK , D'Cruz DavidP . Biological drugs in ANCA-associated vasculitis. International Immunopharmacology2015;27(2):209-12. ">Lutalo 2015</a>; <a href="./references#CD008333-bbs2-0096" title="SouzaAWS , CalichAL , MarizHA , OchtropMLG , BacchiegaABS , FerreiraGA , RêgoJ , PerezMO , PereiraRMR , BernardoWM , Levy RA. Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis. Rev Bras Reumatol Engl Ed.2017;57 Suppl 2:484-496.">Souza 2017</a>), pointing out that there is insufficient evidence regarding use most of biological treatments in ANCA‐associated vasculitis. However, <a href="./references#CD008333-bbs2-0046" title="Silva-FernandezL , LozaE , Martinez-TaboadaVM , BlancoR , Rua-FigueroaI , Pego-ReigosaJM , et al. Biological therapy for systemic vasculitis: a systematic review. Seminars in Arthritis and Rheumatism2014;43(4):542-57. ">Silva‐Fernandez 2014</a> had broader scope and addressed all types of vasculitis and all types of biological therapies. <a href="./references#CD008333-bbs2-0046" title="Silva-FernandezL , LozaE , Martinez-TaboadaVM , BlancoR , Rua-FigueroaI , Pego-ReigosaJM , et al. Biological therapy for systemic vasculitis: a systematic review. Seminars in Arthritis and Rheumatism2014;43(4):542-57. ">Silva‐Fernandez 2014</a> was not focused only on evidence from RCTs, but also included previously published systematic reviews, RCTs, cohort studies and case series. That review had its last search in April 2014 and included two RCTs that we also identified. <a href="./references#CD008333-bbs2-0046" title="Silva-FernandezL , LozaE , Martinez-TaboadaVM , BlancoR , Rua-FigueroaI , Pego-ReigosaJM , et al. Biological therapy for systemic vasculitis: a systematic review. Seminars in Arthritis and Rheumatism2014;43(4):542-57. ">Silva‐Fernandez 2014</a> concluded that etanercept is not effective in maintaining remission in patients with GPA and that large RCTs on biological therapies in systemic vasculitis are needed. <a href="./references#CD008333-bbs2-0024" title="LutaloMK , D'Cruz DavidP . Biological drugs in ANCA-associated vasculitis. International Immunopharmacology2015;27(2):209-12. ">Lutalo 2015</a> was not described as a systematic review. It aimed to summarise both the clinical trials and clinical practice regarding use of biological therapies in the treatment of ANCA‐associated vasculitis. They searched literature up to November 2014, described three of the RCTs that were included in our review (<a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> was still ongoing at the time). <a href="./references#CD008333-bbs2-0024" title="LutaloMK , D'Cruz DavidP . Biological drugs in ANCA-associated vasculitis. International Immunopharmacology2015;27(2):209-12. ">Lutalo 2015</a> concluded that drugs belonging to anti‐TNF‐α agents are not recommended in inducing remission in patients with ANCA‐associated vasculitis and that the data for other biological agents (including those assessed in our review) is limited. The guidelines of the Brazilian Society of Rheumatology, based on a systematic review with literature searched up to October 2016, recommended not to use etanercept in the induction of remission in patients with ANCA‐associated vasculitis (<a href="./references#CD008333-bbs2-0096" title="SouzaAWS , CalichAL , MarizHA , OchtropMLG , BacchiegaABS , FerreiraGA , RêgoJ , PerezMO , PereiraRMR , BernardoWM , Levy RA. Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis. Rev Bras Reumatol Engl Ed.2017;57 Suppl 2:484-496.">Souza 2017</a>). Our review adds to the evidence from previous reviews the results of two studies on anti‐cytokine agents: the results of <a href="./references#CD008333-bbs2-0001" title="JayneD , BlockmansD , LuqmaniR , JiB , GreenY , et al. AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. In: Annals of the Rheumatic Diseases. Vol. 77. 2018:1488. JayneD , BlockmansD , LuqmaniR , MoiseevS , GreenY , et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol2019;71(6):952‐963. JayneD , BlockmansD , Luqmani, R, JiB , GreenY , HallL , et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: A multicenter randomized, placebo-controlled study.. In: Arthritis and Rheumatology. Vol. 69. 2017. NCT01663623. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis. clinicaltrials.gov/ct2/show/study/NCT01663623?term=BREVAS&amp;rank=1 (first received 13 August 2012). ">BREVAS 2018</a> in patients with GPA and the results of <a href="./references#CD008333-bbs2-0003" title="KrishnaR , WestFM , ZappettiD . Is Anti-IL 5 therapy effective in eosinophilic granulomatosis with polyangiitis?Clinical Pulmonary Medicine2017;24(6):267-8. SmithR . Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology2017;56:iii15. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , WechslerME . Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: Post-hoc results of a phase iii randomized, placebo-controlled trial. In: Arthritis Rheumatol. Vol. 69. 2017. SteinfeldJ , MallettS , BrownJ , Bradford ES , YanceyS , Wechsler M. Eosinophilic Granulomatosis with Polyangiitis Patient Characteristics and Clinical Response to Mepolizumab Compared to Placebo. American Journal of Respiratory and Critical Care Medicine2018;197:A3012. SteinfeldJ , BradfordES , BrownJ , MallettS , YanceySW , AkuthotaP , et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019 Jun;143(6):2170-2177. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordC , et al. Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: A phase iii randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:107. WechslerME , AkuthotaP , JayneD , KhouryP , KlionA , LangfordCA , MerkelPA , MoosigF , SpecksU , CidMC , LuqmaniR , BrownJ , MallettS , PhilipsonR , YanceySW , SteinfeldJ , WellerPF , GleichGJ , EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England Journal of Medicine2017;376(20):1921-1932. ">Wechsler 2017</a> on mepolizumab in relapsing or refractory EGPA. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008333-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008333-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008333-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008333-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 1: Mortality" data-id="CD008333-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 1: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 2: Remission" data-id="CD008333-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 2: Remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 3: Durable remission" data-id="CD008333-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 3: Durable remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 4: Disease relapse" data-id="CD008333-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 4: Disease relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 5: Any AE" data-id="CD008333-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 5: Any AE</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 6: Any serious AE" data-id="CD008333-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 6: Any serious AE</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 7: Any withdrawals due to AE" data-id="CD008333-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 7: Any withdrawals due to AE</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 8: Control of asthma symptoms with ACQ6 ‐ change from baseline" data-id="CD008333-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 8: Control of asthma symptoms with ACQ6 ‐ change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 9: Control of sinonasal symptoms with SNOT22 ‐ change from baseline" data-id="CD008333-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 9: Control of sinonasal symptoms with SNOT22 ‐ change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 10: Disease damage in VDI ‐ change from baseline" data-id="CD008333-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: EGPA ‐ mepolizumab vs placebo, Outcome 10: Disease damage in VDI ‐ change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 1: Mortality" data-id="CD008333-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 1: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 2: Remission" data-id="CD008333-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 2: Remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 3: Durable remission" data-id="CD008333-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 3: Durable remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 4: Disease relapse" data-id="CD008333-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 4: Disease relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 5: No disease flare" data-id="CD008333-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 5: No disease flare</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 6: Any AE" data-id="CD008333-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 6: Any AE</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 7: Any non serious AE" data-id="CD008333-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 7: Any non serious AE</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 8: Any severe or serious AE" data-id="CD008333-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 8: Any severe or serious AE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 9: Any solid malignancy" data-id="CD008333-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 9: Any solid malignancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 10: Any withdrawals due to AE" data-id="CD008333-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 10: Any withdrawals due to AE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 11: Treatment response" data-id="CD008333-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: GPA ‐ anticytokine therapy vs control, Outcome 11: Treatment response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 1: Mortality" data-id="CD008333-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 1: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 2: Remission" data-id="CD008333-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 2: Remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 3: Durable remission" data-id="CD008333-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 3: Durable remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 4: Disease flare" data-id="CD008333-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 4: Disease flare </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 5: Any severe or serious AE" data-id="CD008333-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 5: Any severe or serious AE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 6: Any withdrawals due to AE" data-id="CD008333-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 6: Any withdrawals due to AE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 7: Treatment response" data-id="CD008333-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: GPA ‐ sensitivity analysis regarding WGET trial, Outcome 7: Treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: GPA ‐ sensitivity BREVAS withdrawn due to adverse events, Outcome 1: Any withdrawals due to AE" data-id="CD008333-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: GPA ‐ sensitivity BREVAS withdrawn due to adverse events, Outcome 1: Any withdrawals due to AE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 1: Mortality" data-id="CD008333-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 1: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 2: Any remission" data-id="CD008333-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 2: Any remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 3: Durable remission" data-id="CD008333-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 3: Durable remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 4: Disease relapse" data-id="CD008333-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 4: Disease relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 5: Any serious or severe AE" data-id="CD008333-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 5: Any serious or severe AE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008333-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/urn:x-wiley:14651858:media:CD008333:CD008333-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 6: Any withdrawals due to AE" data-id="CD008333-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_t/tCD008333-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Sensitivity analysis ‐ all AAV together, Outcome 6: Any withdrawals due to AE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/media/CDSR/CD008333/image_n/nCD008333-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008333-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mepolizumab compared to placebo for adults with EGPA ANCA‐associated vasculitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mepolizumab compared to placebo for adults with EGPA ANCA‐associated vasculitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (age 18 years and older) with EGPA ANCA‐associated vasculitis<br/><b>Setting:</b> clinical centres<br/><b>Intervention:</b> mepolizumab (300 mg; 3 separate injections every 4 weeks)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With mepolizumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.39<br/>(0.15 to 372.38) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0%<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/>(0 fewer to 0 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During 52 weeks follow‐up, one death was reported in the mepolizumab group and no deaths in placebo group. </p> <p>The low‐certainty evidence suggests that mepolizumab results in little to no difference in mortality. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission for at least 24 weeks<br/>assessed with: BVAS v.3 of 0 (on a scale from 0 to 63)<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 9.50<br/>(2.30 to 39.21) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9%<br/>(6.8 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0% more<br/>(3.8 more to 112.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests mepolizumab results in a large increase of the probability of accruing at least 24 weeks of remission over a 52‐week period. </p> <p>NNTB 4, 95% CI 3 to 8</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Durable remission within the first 24 weeks sustained until week 52<br/>assessed with: BVAS v.3 of 0 (on a scale from 0 to 63)<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 13.00<br/>(1.75 to 96.33) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.1%<br/>(2.6 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.6% more<br/>(1.1 more to 140.2 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that mepolizumab results in a large increase of the probability of durable remission within the first 24 weeks, sustained until week 52. </p> <p>NNTB 6 95% CI 4 to 13</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease relapse<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/>(0.53 to 0.86) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.0%<br/>(43.6 to 70.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4% fewer<br/>(38.7 fewer to 11.5 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab probably results in a reduction in disease relapse.<br/>NNTB 4, 95% CI 3 to 9 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease flares</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.96 to 1.11) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.9%<br/>(90.4 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8% more<br/>(3.8 fewer to 10.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that mepolizumab does not increase any adverse event.<br/>Number of participants reporting similar rates of any AEs in mepolizumab and placebo group (97% vs 94%). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any serious adverse event<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.67<br/>(0.35 to 1.28) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7%<br/>(9.3 to 33.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7% fewer<br/>(17.2 fewer to 7.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that mepolizumab results in little to no difference in any serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any withdrawals due to AEs<br/>follow‐up: 52 weeks<br/>Number of participants: 136<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 2.00<br/>(0.19 to 21.54) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9%<br/>(0.3 to 31.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% more<br/>(1.2 fewer to 30.2 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that mepolizumab does not increase any withdrawals due to AEs.<br/>The study reported similar number of patients withdrawn from mepolizumab and placebo groups due to AEs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ANCA</b> : anti‐neutrophilic cytoplasmic antibodies; <b>CI:</b> Confidence interval; <b>BVAS:</b> Birmingham Vasculitis Activity Score; <b>EGPA:</b> eosinophilic granulomatosis with polyangiitis; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for imprecision: CIs are wide and the number of events was too low to reliably assess optimal information size (OIS); or OIS not met </p> <p><sup>2</sup>Downgraded by one level for imprecision: the number of events was lower than indicated in GRADE guidance </p> <p>AE ‐ adverse event</p> <p>ANCA – antineutrophil cytoplasmic antibody</p> <p>BVAS – Birmingham Vasculitis Activity Score</p> <p>EGPA – eosinophilic granulomatosis with polyangiitis</p> <p>NNTB ‐ number needed to treat for an additional beneficial outcome</p> <p>OR ‐ odds ratio</p> <p>RCT ‐ randomized controlled trial</p> <p>RR ‐ relative risk</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mepolizumab compared to placebo for adults with EGPA ANCA‐associated vasculitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008333-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Active drug (etanercept or belimumab) with standard therapy compared to standard therapy with placebo for adults with GPA ANCA‐associated vasculitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Active drug (etanercept or belimumab) with standard therapy compared to standard therapy with placebo for adults with GPA ANCA‐associated vasculitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study, i.e. 7.7% of total population and not analysed separately)<br/><b>Setting:</b> clinical centres in etanercept study and not reported in belimumab study<br/><b>Intervention:</b> active drug (etanercept: 25 mg twice a week for a median of 25 months or belimumab: 10 mg/kg on days 0, 14, 28 and every 28 days thereafter until 12 months after the last participant was randomised) with standard therapy<br/><b>Comparison:</b> standard therapy with placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With standard therapy and placebo</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With active drug (etanercept or belimumab) with standard therapy</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/>Number of participants: 285<br/>(2 RCTs) </p> <p>WGET 2005 follow‐up: 27 months; BREVAS 2018 follow‐up: approximately up to 4 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Peto OR 2.45<br/>(0.55 to 10.97) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%<br/>(0.8 to 15.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0% more<br/>(0.6 fewer to 13.9 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Five deaths was reported in active drug (etanercept or belimumab) with standard therapy group and two deaths in standard therapy with placebo group. </p> <p>Low‐certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy when compared with standard therapy does not increase/reduce mortality. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission (number of patients with remission)<br/>assessed with: BVAS/WG = 0 </p> <p>WGET 2005 follow‐up: 27 months<br/>Number of participants: 180<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/>(0.89 to 1.07) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.5%<br/>(82.2 to 98.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8% fewer<br/>(10.2 fewer to 6.5 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy when compared with standard therapy with placebo may have little or no effect on remission. However, any effect is likely to be small. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Durable remission<br/>assessed with: BVAS/WG = 0 for ≥ 6 months<br/>follow‐up: 27 months<br/>Number of participants: 174<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.93<br/>(0.77 to 1.11) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.0%<br/>(58 to 83.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3% fewer<br/>(17.3 fewer to 8.3 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐certainty evidence suggests that etanercept added to standard therapy when compared with standard therapy and placebo may have little or no effect on durable remission. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major relapse<br/>assessed with: BVAS (experiencing at least 1 major BVAS item) </p> <p>follow‐up: year 2 week 28<br/>Number of participants: 105<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 2.94<br/>(0.12 to 70.67) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0%<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/>(0 fewer to 0 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐certainty evidence suggests that belimumab added to standard therapy when compared with standard therapy and placebo does not increase/reduce major relapse. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease flare<br/>assessed with: BVAS/WG ‐ increase of at least one point in scale<br/>follow‐up: 27 months<br/>Number of participants: 180<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/>(0.76 to 1.27) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.0%<br/>(43.4 to 72.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1% fewer<br/>(13.7 fewer to 15.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Etanercept added to standard therapy when compared with standard therapy with placebo probably does not reduce disease flare. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event follow‐up: approximately up to 4 years</p> <p>Number of participants: 105<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>RR 1.12</p> <p>(0.97 to 1.29)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>82.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.5%</p> <p>(2.5 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9% more</p> <p>(2,5 fewer to 24 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The low‐certainty evidence suggests that belimumab added to standard therapy when compared with standard therapy with placebo may result in little or no difference in any AE. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe or serious AE (grade 3, 4 or 5)<br/>assessed with: the National Cancer Institute Toxicity Grading Scale </p> <p>WGET 2005 follow‐up: 27 months; BREVAS 2018 follow‐up: approximately up to 4 years<br/>Number of participants: 285<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.80 to 1.27) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.6%<br/>(38 to 60.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/>(9.5 fewer to 12.8 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy when compared with standard therapy with placebo may result in little or no difference in severe or serious AE (grade 3, 4 or 5). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any withdrawals due to AE<br/>assessed with the National Cancer Institute Toxicity Grading Scale </p> <p>WGET 2005 follow‐up: 27 months; BREVAS 2018 follow‐up: approximately up to 4 years<br/>Number of participants: 285<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 2.66<br/>(1.07 to 6.59) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2%<br/>(4.5 to 27.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0% more<br/>(0.3 more to 23.5 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The low‐certainty evidence suggests that active drug (etanercept or belimumab) added to standard therapy when compared with standard therapy with placebo results in a slight increase in any withdrawals due to AE. </p> <p>NNTH 15, 95% CI 8 to 100</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ANCA</b> : anti‐neutrophilic cytoplasmic antibodies; <b>CI:</b> Confidence interval;<b>BVAS/WG:</b> Birmingham Vasculitis Activity Score for Wegener's Granulomatosis; <b>GPA:</b> granulomatosis with polyangiitis; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for imprecision: optimal information size (OIS) not achieved; low number of events; confidence intervals very wide or indicating both harm and benefit </p> <p><sup>2</sup>Downgraded by one level due to high risk of selective outcome reporting bias in both studies </p> <p><sup>3</sup>Downgraded by one level for imprecision: OIS criteria are met, but the CIs are very wide; or OIS not achieved, and confidence interval indicates both harm and benefit </p> <p>AE ‐ adverse event</p> <p>ANCA – antineutrophil cytoplasmic antibody</p> <p>BREVAS ‐ Belimumab in Remission of VASculitis</p> <p>BVAS – Birmingham Vasculitis Activity Score</p> <p>BVAS/WG – Birmingham Vasculitis Activity Score for granulomatosis with polyangiitis</p> <p>GPA – granulomatosis with polyangiitis</p> <p>NNTH ‐ number needed to treat for an additional harmful effect</p> <p>OR ‐ odds ratio</p> <p>RCT ‐ randomized controlled trial</p> <p>RR ‐ relative risk</p> <p>WGET ‐ Wegener's Granulomatosis Etanercept Trial</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Active drug (etanercept or belimumab) with standard therapy compared to standard therapy with placebo for adults with GPA ANCA‐associated vasculitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008333-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Infliximab compared to rituximab for adults with refractory GPA ANCA‐associated vasculitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to rituximab for adults with refractory GPA ANCA‐associated vasculitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> infliximab (3 mg/kg on days 1 and 14, before the response assessment on day 42; further treatment depending on the response)<br/><b>Comparison:</b> rituximab (0.375g/m<sup>2</sup> on days 1, 8, 15 and 22 before the response assessment at month 2; further treatment depending on the response) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With rituximab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With infliximab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/>follow‐up: 12 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.88<br/>(0.05 to 15.51) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.0%<br/>(0.6 to 193.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% fewer<br/>(11.9 fewer to 181.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One death was reported in each group.</p> <p>The evidence is very uncertain about the effect of infliximab when compared to rituximab on mortality. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission<br/>assessed with: BVAS=0<br/>follow‐up: 12 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.44<br/>(0.11 to 1.81) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.0%<br/>(5.5 to 90.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.0% fewer<br/>(44.5 fewer to 40.5 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of infliximab when compared with rituximab on remission at month 12. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Durable remission during additional follow‐up beyond 12 months<br/>follow‐up: mean 30.6 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.22<br/>(0.03 to 1.60) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.0%<br/>(1.5 to 80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.0% fewer<br/>(48.5 fewer to 30 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of infliximab when compared with rituximab on durable remission during additional follow‐up beyond 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease flare/relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>This outcome was not reported in included trial.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>The total number of any AEs was not reported in the study.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe AEs<br/>assessed with: the World Health Organization classification (2003)<br/>follow‐up: 12 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.78<br/>(0.20 to 16.10) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.3%<br/>(2.5 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8% more<br/>(10 fewer to 188.8 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of infliximab when compared with rituximab on any severe AEs. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any withdrawals due to AEs<br/>assessed with: the World Health Organization classification (2003)<br/>follow‐up: 12 months<br/>Number of participants: 17<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 2.70<br/>(0.13 to 58.24) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0%<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/>(0 fewer to 0 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of infliximab when compared with rituximab on any withdrawals due to AEs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>GPA:</b> granulomatosis with polyangiitis; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to risk of bias – unclear randomisation and concealment, no blinding and unclear selective outcome reporting </p> <p><sup>2</sup>Downgraded by two levels for imprecision: optimal information size (OIS) not met and CI indicates both harm and benefit; and/or low number of events </p> <p>AE ‐ adverse event</p> <p>ANCA – antineutrophil cytoplasmic antibody</p> <p>BVAS – Birmingham Vasculitis Activity Score</p> <p>GPA – granulomatosis with polyangiitis</p> <p>OR ‐ odds ratio</p> <p>RCT ‐ randomized controlled trial</p> <p>RR ‐ relative risk</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Infliximab compared to rituximab for adults with refractory GPA ANCA‐associated vasculitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/full#CD008333-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008333-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">EGPA ‐ mepolizumab vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Any remission (for at least 1 week)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.62, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Remission for at least 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.50 [2.30, 39.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Durable remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Disease relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Any AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Any event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Any event related to trial agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Any serious AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Any serious event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Any serious event related to trial agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Any withdrawals due to AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Control of asthma symptoms with ACQ6 ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.60, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Control of sinonasal symptoms with SNOT22 ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.66 [‐10.69, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Disease damage in VDI ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.37, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">EGPA ‐ mepolizumab vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008333-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">GPA ‐ anticytokine therapy vs control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.55, 10.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Infliximab vs rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.05, 15.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Etanercept vs placebo, remission at any time during study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Infliximab vs rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.11, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Durable remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Etanercept vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Infliximab vs rituximab long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.03, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Disease relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Any relapse ‐ belimumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.27, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Major relapse ‐ belimumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [0.12, 70.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 No disease flare <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Etanercept vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Any AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Any non serious AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Belimumab vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Any severe or serious AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.80, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Infliximab vs rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.20, 16.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Any solid malignancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 During trial and follow up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [1.08, 7.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 During trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.29 [0.76, 232.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.3 During follow up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.54, 4.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Any withdrawals due to AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [1.07, 6.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Infliximab vs rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.13, 58.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Sustained low level of disease activity (Etanercept vs placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Partial remission (infliximab vs rituximab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.07, 12.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">GPA ‐ anticytokine therapy vs control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008333-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">GPA ‐ sensitivity analysis regarding WGET trial</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [0.55, 11.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Etanercept vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.90, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Durable remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Etanercept vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Disease flare <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Etanercept vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.77, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Any severe or serious AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.80, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Any withdrawals due to AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [1.08, 6.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Sustained low level of disease activity (Etanercept vs placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">GPA ‐ sensitivity analysis regarding WGET trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008333-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">GPA ‐ sensitivity BREVAS withdrawn due to adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Any withdrawals due to AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.80, 4.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">GPA ‐ sensitivity BREVAS withdrawn due to adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008333-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analysis ‐ all AAV together</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.64, 7.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 EGPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.39 [0.15, 372.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 GPA active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.55, 10.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 GPA infliximab vs rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.05, 15.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Any remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.36, 3.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 EGPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.62, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 GPA active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 GPA infliximab vs rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.11, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Durable remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.20, 8.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 EGPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.00 [1.75, 96.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 GPA active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 GPA infliximab vs rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.03, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Disease relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.54, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 EGPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.53, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 GPA active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.27, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Any serious or severe AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.78, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 EGPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.35, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 GPA active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.80, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.3 Infliximab vs rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.20, 16.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Any withdrawals due to AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.13, 5.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 EGPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.19, 21.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 GPA active drug vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [1.07, 6.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.3 GPA infliximab vs rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.13, 58.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analysis ‐ all AAV together</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008333.pub2/references#CD008333-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008333.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008333-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008333-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008333-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008333-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008333-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008333-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008333-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008333-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008333\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008333\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008333\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008333\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008333\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008333.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008333.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008333.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008333.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008333.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727434924"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008333.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727434928"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008333.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eabfc3b4cf573',t:'MTc0MDcyNzQzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 